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Overview of thesis 
Rheumatoid arthritis (RA) is one of the most common forms of chronic inflammatory arthritis 
and often results in joint damage, physical disability and premature mortality. The incidence 
of RA is increasing in developing countries, especially in urban areas amongst lower socio-
economic groups. There is a dearth of data on non-communicable diseases such as RA in South 
Africa (SA) as resources and research is concentrated on addressing the high burden of 
communicable diseases due to human immunodeficiency virus (HIV) and tuberculosis (TB) 
compounded with addressing high maternal and infant mortality rates. Therefore despite the 
severity and resultant functional disability, RA remains poorly understood and often 
mismanaged.  
This study aims were to understand the natural history of patients with RA treated in a public 
sector tertiary clinic. The objectives of this retrospective study are to describe the demographic 
profile, disease activity, drug management and comorbid disease profile in patients with 
established RA attending a dedicated rheumatic clinic at King Edward VIII Hospital in Durban.  
A retrospective chart review was conducted of the files of all RA patients attending the 
arthritis clinic at King Edward VIII Hospital, for a period of at least ten years. The 
demographic data, serological status, current disease activity, functional class, co-morbid 
diseases, and treatment were recorded on a structured data collection tool.  
In this study, Indians comprised the majority (n=81, 58.7%) followed by Blacks (n = 51, 
36.9%). All the patients met the clinical criteria for RA on the initial visit, with 73 (63.5%) 
having a positive rheumatoid factor (RF). Synovitis was still observed in 35.5% of patients at 
their last visit and in these patients the C-reactive protein remained elevated at ≥ 16 mg/dL (p 
< 0.0001). Radiographs showed a significant deterioration in terms of erosions between the 
two time points (p < 0.021). Hypertension was the most frequent co-morbid disease seen in 
96 (69.6%) patients.   
There were several limitations as this was a retrospective study and therefore there were a 
number of files that had incomplete or missing data. The clinical assessment of disease was 
performed by several clinicians and inter-observer variability was another shortcoming. 
Further the study was limited to the public sector only and potentially excluded other 





This study highlights the need for better and tighter RA control in the SA public sector and 
the need for prospective studies with adequate representation of all ethnic groups to evaluate 
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Chapter 1: Literature Review 
Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown aetiology 
characterized by a symmetrical, peripheral polyarthritis. It is the most common form of 
chronic inflammatory arthritis and untreated results in joint damage, physical disability and 
premature mortality (1, 2). 
Autoimmune in nature, it is a systemic disorder associated with several extra-articular 
manifestations including but not limited to lung involvement, peripheral neuropathy, 
vasculitis, eye changes and haematological abnormalities. Rheumatoid nodules, one of the 
most typical diagnostic features of RA, are found in 20-30% of patient who always will have 
a positive test for rheumatoid factor (1, 2). 
Pathogenesis 
While the exact cause of RA remains elusive, an infective cause from an ubiquitous agent in 
a genetically susceptible host may be the underlying trigger. Additionally although several 
causative agents and their products (e.g. heat shock proteins) have been linked to RA via a 
process of molecular mimicry, most notably Epstein-Barr virus, to date no compelling 
evidence has emerged (1). 
In contrast, the pathogenic mechanisms of synovial inflammation in RA are better 
understood, and is thought to be driven by immune dysregulation, inflammation and a 
breakdown in self-tolerance (3). A key pathway in RA inflammation, is the overproduction 
and overexpression of tumour necrosis factor (TNF), which drives both synovial 
inflammation and joint destruction leading to excessive production of interleukin-6 (IL-6), an 
important pro-inflammatory mediator. Additionally, IL-1 is also abundantly expressed in RA 
and promotes activation of leucocytes, endothelial cells, chondrocytes and osteoclast in the 
pannus itself. The release of inflammatory mediators from the synovium results in malaise, 
fatigue and elevated levels of acute-phase reactants (APR) (1, 3, 4) 
The rheumatoid synovium, the pathognomic feature of disease in RA is hyperplastic and 
infiltrated by lymphocytes and mesenchymal cells. Fibroblast like synoviocytes resident in 




of cytokines and chemokines that promote a permissive micro-environment that sustains T - 
cell and B - cell survival and ongoing cartilage damage and erosion to underlying bone (4). 
This inflammatory response results in auto-antibody production and rheumatoid factor (RF) 
auto-antibodies are found in 75 - 80% of RA patients at some time during the course of their 
disease. Immunoglobulin (Ig), IgM and IgA rheumatoid factors are pathogenic markers 
directed against the Fc fragment of IgG (1). High titres are predictors of a severe disease and 
correlate with extra-articular manifestations. Although the levels of RF may fluctuate with 
disease activity, RF is not used as a measure of disease activity (5). 
Additionally, increasingly important types of antibodies, against citrullinated peptides (CCP) 
have been recognized. Anti-cyclic citrullinated peptide antibodies (ACPA) are produced in 
the liver and are directed against deaminated peptides (6). Studies suggest that ACPA have a 
greater sensitivity (50-75%) and specificity (>90%) than RF and are of particular diagnostic 
benefit in patients who test RF antibody negative. Anti-cyclic citrullinated peptide are better 
predictors of poor prognostic features such as progressive joint destruction, erosive disease 
and high levels of disease activity (7, 8). Additionally ACPA are a predictive tool for RA, 
and may precede the clinical manifestations of disease by up to 14 years.  
Individuals with RA susceptibility genes including HLA-DRB1, who are also smokers are at 
a significantly higher risk of developing ACPA (9). Distinct differences are observed in the 
synovium of patients who test positive for RF and anti-CPP, compared to autoantibody 
negative patients. Auto-antibody positive disease has increased lymphocytes whereas those 
with ACPA negative RA are more likely to have fibrosis and increased thickness of the 
synovial layer (10). 
Although an important diagnostic marker, RF and ACPA are found in approximately 5% and 
1.5% of normal individuals respectively, and therefore alone are insufficient for the diagnosis 
of RA (5, 6). 
In the last two decades, the understanding of the pathogenesis of RA has significantly 
advanced with the identification of disease related genes and deciphering of the involved 
molecular pathways (1, 4) 
There is a strong genetic correlation seen in RA, with at least a 50% risk of developing the 




12 – 15% and amongst first degree relatives is 2 - 10 times greater than the general 
population (1). 
Recently there has been significant progress in identifying the genetic regions and single 
nucleotide polymorphisms associated with RA. Currently more than 30 genetic regions are 
associated with RA, the major ones being PTPN22 and the class II major histocompatibility 
complex (MHC), the human leucocyte antigen; HLA – DR gene. Further, genetic studies 
show differences in the ACPA status of patients with RA, related to the number of specific 
HLA - DRB1 alleles. These HLA alleles share a common motive, an amino acid sequence at 
positions 70 - 74 in the third hyper-variable regions of the HLA - DRB chain, which is known 
as the shared epitope (11, 12). 
Genetic studies of the HLA - DR alleles show that DR4 is the most common association 
among patients attending rheumatology clinics in South Africa (SA). A study in 1995, in 
Durban Blacks of Zulu descent, found a 44% frequency of DR4 in RA patients compared to 
10% in controls (13, 14). Similarly studies from Cape Town in Whites, Blacks and patients of 
Mixed Ancestry also showed a consistent association of HLA – DR4 in all population groups 
with a relative risk of 3,2 in Whites, 3,9 in Blacks and 3,7 in patients of Mixed Ancestry with 
RA (15).  
Environmental risk factors 
Several environmental risk factors are thought to increase the risk of RA, and the best studied 
amongst them is smoking. Smoking doubles the risk of developing RA, especially women 
who smoke cigarettes have a nearly 2.5 times greater risk of RA. Interestingly the risk from 
smoking is almost exclusively related to RF and ACPA positive disease (1). 
Other potential environmental risk factors include; alcohol intake, coffee intake, vitamin D 
status, oral contraceptive use and low socioeconomic status, although supporting evidence for 
these other factors is weak (16).  
Urbanization has also been associated with an increased prevalence of RA, possibly due to 
the effects of air pollution.  A study from the Harvard Medical School found an increased risk 
of RA in women  exposed to traffic pollution and who lived within 50 meters of a road (17). 
Additionally studies in urban, suburban and rural populations in Taiwan similarly suggest 
that environmental factors such as air pollution may affect RA susceptibility in individuals 





The peak incidence of the onset of RA is in the fourth decade of life and the disease is three 
times more common in women than men, with prevalence increasing with age in both sexes. 
The highest prevalence is seen in women older than 65 years, suggesting hormonal factors 
may play an important role (1). 
Rheumatoid arthritis affects approximately 0.5 - 1% of adults in the developed world and 
there is significant geographic and ethnic variation within countries (Figure 1) (1). In the 
Native American Pima Indians of North America, an extremely high prevalence has been 
shown of up to nearly 7% in some studies. In contrast, other population studies from Africa 
and Asia show lower prevalence rates in the range of 0.2 – 0.4% (19). 
 
Figure 1 Global prevalence rates of rheumatoid arthritis (1) 
There are limited studies from Africa on RA and these are from a few countries (SA, Nigeria 
and Uganda). Traditionally RA was thought to be rare in Africa and to have a milder disease 
course compared to the developed world, however recent studies suggest an increasing 
incidence of RA in Africa.  
A systematic literature review of the burden of RA in Africa showed a prevalence of 0.36% 
in the 1990’s, which translated to a burden of 2.3 million affected individuals. Based on the 
above prevalence rates it is expected that by 2019, this figure would increase to 0.42% and 




underestimation as it is calculated using hospital based studies which under-report the 
prevalence by about six times in comparison to population based studies (20). 
The exact incidence of RA in Africa presently remains uncertain but there is increasing 
evidence that the prevalence of RA is increasing in the indigenous populations of East, Central 
and South Africa although it remains rare in West Africa (20, 21). 
Studies from SA, have shown a higher disease activity and prevalence in the Black urban 
community of Soweto (0.9%) compared to rural communities; Tswana in Western Transvaal 
(0.1%), Xhosa in Eastern Cape (0.68%) and Sotho’s in Lesotho (0.3%)). Interestingly, the 
prevalence rate has been documented to be 0% amongst the Venda peoples. The reasons for 
the lower rates of RA in rural African populations remains unclear but it supports 
environmental factors in the pathogenesis of RA (22-24). 
The mean age of onset of RA at 36.6 years (range 17 - 54) in SA Blacks is significantly lower 
than the 44.2 years reported in Caucasians, but similar to the younger mean age of onset of 33 
years reported in Nigerians (25, 26). 
Similar to developed countries, there is a greater female preponderance of RA in developing 
countries, however the ratio is much higher and more than double that reported in the 
Western world. Tikly et al, in Soweto (2003), found a gender ratio of 6.9:1 amongst 
established RA patients, which is consistent with observations from Latin America and other 
developing countries (27-29).  
Clinical manifestations and systemic consequences of rheumatoid arthritis 
Rheumatoid arthritis causes a polyarticular symmetrical inflammation of the joints, tendons 
and bursae and presents with pain, swelling and early morning joint stiffness (EMS), usually 
lasting more than one hour. The earliest affected joints are usually the small joints of the 
hands and feet. Constitutional features frequently accompany joint involvement and include 
fatigue, fever, weight loss and lymphadenopathy (2).     
In approximately one third of patients there may be an atypical presentation with either an 
initial mono / oligo-articular involvement or an asymmetrical pattern of disease. 
Extra-articular manifestations may occur during any stage of RA in up to 40% of patients. 
Predictors for extra-articular involvement include smoking, sero-positive RF disease and 




articular manifestations are subcutaneous nodule, secondary Sjogren’s syndrome, pulmonary 
nodules and anaemia (1). A study from Cape Town in 1989, confirmed a similar spectrum of 
extra-articular disease in Black patients with anaemia being the most common finding (40%), 
followed by subcutaneous nodules (25%) and keratoconjuctivitis sicca (10%) (13). 
Osteoporosis secondary to chronic inflammation and glucocorticoid therapy is a frequent 
complication in RA and independently affects functional capacity, apart from increasing the 
fracture risk. International studies have confirmed  a 22% higher incidence of osteoporosis of 
the hip or lumbar spine in RA patients compared with the general population (31), whilst 
another study demonstrated a significantly increased risk of osteoporotic fracture in RA 
patients independent of CS use (32). 
Local studies from Cape Town in premenopausal women with RA, also show that 
generalized bone loss is a systemic feature of RA, with significant vertebral and femoral bone 
loss seen in young patients with an overall prevalence of osteopenia of 6% (33). Further, the 
bone loss at the spine and femur is aggravated by CS therapy (33). Studies also show that the 
prevalence of metacarpal osteopenia was 55% in young RA patients and that this may be a 
useful potential measure of disease activity in RA patients (34). 
Comparative studies amongst patients receiving high dose CS therapy for systemic lupus 
erythematosus (SLE) to low dose CS therapy for RA demonstrated that metacarpal bone mass 
was significantly higher in patients with SLE than RA. This was despite the larger cumulative 
doses of CS for longer periods in SLE suggesting that in RA, bone loss is a feature of disease 
severity rather than of CS therapy (35). 
Radiological changes 
Radiographs although useful in diagnosis are more useful to detect disease damage and 
disease progression. Untreated RA will lead to bone erosions in 80% of patients within one 
year of diagnosis. Erosive bone disease is associated with prolonged inflammation and is a 
measure of disease activity (36). Juxta-articular erosions characterize progressive established 
RA and are usually irreversible. Erosions are readily identified by conventional radiography 
and two typical erosions are sufficient to confirm the diagnosis, while extensive ongoing 
damage on radiographs suggests poorly controlled disease (37). Radiographs should be 




Recently ultrasound (US) and magnetic resonance imaging (MRI) are being increasingly 
used, as they can assess both reversible and irreversible structural changes compared to 
conventional radiographs. The advantages are improved sensitivity in detecting synovitis, 
joint space narrowing and erosions earlier. The addition of power colour doppler ultrasound 
allows for the detection of increased joint vascularity indicative of inflammation (39). 
Magnetic resonance imaging (MRI) allows a three-dimensional perspective and precise 
assessment of the bony and soft tissue structures within a targeted joint. The main ‘activity’ 
findings detected by MRI include synovitis, tenosynovitis and bone marrow oedema (BME), 
while the ‘damage’ findings include bone erosions and joint space narrowing. Tamai et al. 
reported a scoring system using baseline ACPA and / or RF, MRI findings of symmetrical 
synovitis and MRI BME and / or bone erosion to predict early RA with 82.5% sensitivity and 
84.8% specificity. However with MRI the RA criteria are not uniformly defined and this 
together with cut-off values in MRI scoring systems requires further research (40). 
Laboratory investigations 
The severity of RA is determined by a combination of clinical examination, radiological 
findings and use of biologic markers which include APR, the erythrocyte sedimentation rate 
(ESR) and the C-reactive protein (CRP). The APR describes the local and systemic 
inflammatory and repair processes that accompany inflammation (37).  
Although the ESR level is widely used and it correlates with disease activity, and it is useful 
for monitoring therapeutic response; its use is limited by the size, shape and number of red 
blood cells as well as other plasma constituents such as immunoglobulins all of which also 
affect ESR levels in any given patient (41). 
The CRP is a more objective measure of disease activity and is the preferential acute phase 
marker, however an increase in both CRP and ESR is a stronger indication of radiological 
progression than that of CRP alone (42). Vd Heijde et al, showed that an absence of 
radiographic joint progression after two years could be correctly predicted in 83% of the 
patients using a combination of disease activity at presentation; ESR, CRP, disease activity 
score (DAS) and DR4 and RF positivity (43). Additionally, Yildirim et al, reported 
significant correlations between serum APR levels and disease activity based on the DAS 28 
(a composite disease activity score that combines information about swollen and tender 




These markers of systemic inflammation have also been found to independently add to the 
risk for cardiovascular (CV) death in RA. Observational studies show an increased risk of 
cardiovascular disease (CVD) that correlates with the activity and duration of the RA as 
measured by APR (45). 
Other disease activity markers include a low serum haemoglobin (46) and Mody et al, (1989) 
reported anaemia as the most common extra-articular manifestation of RA in Black South 
Africans (13). It is postulated that the anaemia is mediated by inflammatory cytokines, 
particularly IL-6 (47). Similarly, a reactive thrombocytosis associated with active RA is most 
likely due to the pro-inflammatory effects of IL-1β and IL-4 (48). 
Diagnostic criteria 
The understanding of the pathogenic mechanisms of RA has led to the development of new 
therapeutic drugs and the understanding that early therapeutic intervention improves clinical 
outcomes and reduces disability. In an attempt to ensure early recognition of RA in 2010, the 
American College of Rheumatology (ACR) and European League against Rheumatism 
(EULAR) developed a new classification system for RA, with the goal of identifying patients 
who would benefit from early effective intervention as the previous ACR1987 criteria were 
limited by poor sensitivity and specificity for classification of patients with early 
inflammatory arthritis as having RA (49). 
The new diagnostic classification compared to the old 1987 criteria improve sensitivity in 
detecting early disease by focusing on the early features of disease that are associated with 
persistent and / or erosive disease. In an attempt to improve the recognition of RA, in 2010, 
the new criteria were revised to be more specific about the joint involvement, serology, APR 










Table 1. ACR/EULAR 2010 Rheumatoid Arthritis Classification Criteria (49) 
 
Disease activity assessment 
The success of therapy for RA relies on the goals of treatment to be specified in advance and 
to assess response timeously and objectively. There are several methods of scoring disease 
activity in RA, where the clinical examination of tender and swollen joints, global 
assessments and laboratory investigations are combined into a composite score (50, 51). 
Common indicators of disease activity in RA include: 
 Pain 
 Duration of morning stiffness 
 Fatigue 
 Measures of function 
 Swollen and tender joint counts 
 Patient and evaluator global assessment of disease activity 
 ESR and CRP 
The three validated scores currently in clinical use in SA are the DAS-28, the Simplified 
Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) (51), and 





Table 2. Composite measures of disease activity (37) 
 
These scores allow classification of RA disease into a state of remission or low, moderate or 
high disease activity and thereby provide a simple tool for assessing disease at each visit to 
guide therapeutic decisions. The level of disease activity is an important indicator of 
functional outcome, joint damage and radiographic progression. 
The SDAI and CDAI have been validated in several cross sectional cohorts and are accurate 
reflections of disease activity, sensitive to change and feasible to perform in all clinical 
settings. Further, the Pearson correlation analysis showed excellent correlation between the 
DAS28, SDAI and CDAI scores and patients disease activity levels (52, 53). The advantage 
of the CDAI is that it is the only composite score that does not incorporate an APR and can 
therefore be conducted at any time.  
Additionally the ACR response criteria is a set of standard criteria which measure clinical 




in the number of tender and swollen joints and a 20% improvement in at least three of the 
following five areas : the APR, the physician’s global assessment of disease status, the 
patients assessment of pain, the patients assessment of function and the patients global 
assessment of disease status. Similarly the ACR 50 and 70 will report a 50% and 70% 
improvement in the above parameters (50). 
Both active and established RA have a substantial effect on physical functioning, therefore 
instruments designed to measure physical functioning are useful indicators of disease 
severity.  
Measuring functional ability in chronic arthritis is challenging and the importance of 
standardized measures of functional capacity have been recognized. The criteria for 
evaluation of such instruments include methods for quantification, reliability, validity and 
precision. There is no one preferred method and almost all of the current instruments measure 
health status, disease activity and functional status (54).  
In a local study comparing functional changes to changes in measures of disease activity it 
was noted that functional disability is related to activity and not chronicity. A number of tools 
have been used previously including the Lansbury systemic index, Keitel functional index 
and the Ritchie articular index to measure overall function in RA i.e. disease activity and 
function (55). 
The Health Assessment Questionnaire (HAQ) is a comprehensive tool designed to assess 
patient disability, discomfort, medication, side effects, cost and mortality and has is recently 
used in clinical practice in the present time (50). Of these components, only the HAQ 
Disability Index (HAQ-DI) is used frequently in clinical trials and clinical practice. It 
evaluates a patients’ ability to perform activities of daily living through their self-reported 
answers to 20 questions designed to assess upper or lower extremity use (50). 
The modified ACR 1991 global functional scale has been shown to correlate closely with the 
HAQ. It is a useful and accepted score to describe the global functional consequences of RA 
especially with regard to assessing physical and work disability (56).  
Functional class, although not sensitive enough to detect small changes in functional 
capacity, is a frequently used tool for the purpose of classifying patients at entry into clinical 




(ARA) criteria for the classification of global functional status were validated by Hochberg et 
al, in 1992 and the differences are tabulated in Table 3 (56). 
Table 3. Comparison of the ARA 1949 and ACR 1991 ‘Global Functional Scale (56)
 
Rheumatoid arthritis and associated co-morbid disease 
The association between RA and non-communicable disease (NCD) is well established and 
on average the established RA patient has two or more co-morbid conditions, which play a 
pivotal role in RA management and outcomes. The NCD’s associated with RA are 
cardiovascular disease (CVD), infections, lymphoproliferative malignancy, gastrointestinal 
disease and osteoporosis (58).  
The greater the number of co-morbid illnesses, the higher the medical costs, subsequent 
disability and mortality risk. Michaud and Wolfe in their seminal report on “Comorbidities in 
rheumatoid arthritis” noted that; “It should be the responsibility of the rheumatologist to take 
this and the risk of additional conditions into account when treating the patient”(59). 
Bishri et al, found in a relatively small study that the most common co-morbid conditions in 
RA were hypertension (35.9%), diabetes (30.9%) osteoporosis (25.8%) and dyslipidaemia 
(19.4%) (60). Similarly Solomon et al. (1995) found that hypertension was the most common 




Accumulating evidence suggests that atherosclerosis and CVD are truly inflammatory 
disorders sharing a common pathophysiology with synovial inflammation and pannus 
formation that characterize RA. Indeed it has been suggested that atherosclerosis and CVD be 
considered “extra-articular manifestations” of RA. Overlapping pathogenic features of the 
two diseases include the predominant role of pro-inflammatory cytokines (e.g. TNF-alpha 
and IL-6), elevated serum levels of APR (CRP, fibrinogen and serum amyloid), abnormal 
endothelial cell function and neoangiogenesis. This unchecked cellular dysregulation is 
postulated to account for the increased prevalence and severity of coronary calcification in 
RA and therefore it is not surprising that CVD is the leading cause of death in patients with 
RA (58, 62, 63). 
Cardiovascular disease risk in RA is similar to CVD risk in diabetes mellitus (DM) with both 
appearing to be of equal frequency and severity (63). 
An additional risk factor in RA is that some of the medications used for treatment may have 
dual effects on risk for CV morbidity. This is exemplified by the use of corticosteroids which 
although they decrease CV complications in RA by decreasing inflammation, they also 
increase CV risk by promoting pro-atherosclerotic lipid profiles, hypertension and insulin 
resistance (63).  
It is now widely accepted that atherosclerosis in RA is associated with both traditional CV 
risk factors such as age and hypertension, as well as non-traditional risk factors of chronic 
inflammation (64). 
Management of rheumatoid arthritis 
The EULAR “treat to target” guidelines recommend remission as the target of therapy in all 
patients with RA regardless of early or established disease. These guidelines, however, do 
recognize that a state of low disease activity may be an acceptable alternative target, 
especially in patients with long standing disease and the aim of treatment is minimization of 
disease activity with disease modifying anti-rheumatic drugs (DMARDs) that slow or prevent 
structural progression of RA (30, 65). 
Achieving and maintaining low disease activity in the shortest time period using single or 
combination DMARD’s, improves long term outcomes and is a cost effective strategy 




The most commonly used DMARD’s in the past were gold, penicillamine and minocycline; 
which all produced a slow response with an associated high level of toxicity, resulting in low 
compliance rates. Further due to their varying degrees of success and inconsistent clinical 
efficacy they are no longer used (1, 30). 
Hydroxychloroquine (HCQ) and sulphasalazine (SSZ) were subsequently introduced and 
were used for early mild disease or as adjunctive treatment (1). Hydroxychloroquine is not 
available in SA and chloroquine is used instead, which local anecdotal experience shows as 
having equivalent efficacy to hydoxychloroquine. However neither HCQ nor chloroquine 
have been shown to delay radiographic progression and are therefore not considered to be a 
true DMARD, while SSZ has been shown in randomized controlled trials to reduce 
radiographic progression of disease (1, 67, 68). 
The introduction of methotrexate (MTX) and its widespread use in the late 1980’s, 
dramatically changed the therapeutic landscape in RA. Methotrexate is regarded as the 
anchor drug in RA, it is effective as monotherapy and is the benchmark for testing efficacy 
and safety of all new DMARDs. Methotrexate is administered as weekly therapy, usually 
between 7.5 to 25mg weekly (30). 
Several studies show good long term compliance and remission on MTX and Choi et al, 
showed a 60% overall reduction in mortality in subjects on MTX (69). Additionally a 
systematic literature review on the long term safety of MTX monotherapy in patients with 
RA demonstrated good tolerability of the drug and favourable long term safety (69-72). Data 
on MTX use and compliance show that approximately 60% of patients receiving high dose 
MTX (12.5 mg per week) still use the drug six years later, and in a separate twelve year 
follow-up study 53% of patients continued to take MTX (irrespective of any periods of 
temporary discontinuation) (73).                                                                                       
Methotrexate has several adverse effects, which may be dose dependent. Adverse effects of 
MTX may be minor (e.g. nausea) or more serious (e.g. hepatotoxicity, blood dyscrasias and 
interstitial lung disease). Monitoring of adverse effects include pre-treatment screening and 
subsequent safety recording of full blood counts and liver function tests throughout the 
course of therapy (1). 
Although the treatment of choice, if MTX cannot be tolerated, or results in adverse reactions 




Leflunomide is a pyrimidine synthesis inhibitor and clinical trials show clinical efficacy 
similar to that of MTX as monotherapy or in combination therapy (1). 
Disease modifying anti-rheumatic drugs may be combined to improve efficacy (67, 68). The 
combination of MTX, SSZ and HCQ – is termed triple therapy. A randomized trial 
comparing combination therapy with single drug therapy with MTX in early RA, showed 
combination therapy was more effective without increasing toxicity risk in inducing RA 
remission in early disease (68). 
Biological agents 
The introduction of the biological DMARDs, which are intravenous proteins that target 
cytokines and cell surface molecules, has revolutionized the treatment of RA. They may be 
broadly classified into TNF inhibitors and non – anti - TNF agents and these include B cell 
targeted therapy against CD 20 (rituximab), T cell co-stimulation blockade with the fusion 
protein (abatacept) and IL-6 receptor inhibition (tocilizumab) (1). 
Studies have shown that the combination use of MTX and biological agents makes clinical 
remission and radiographic non-progression a realistic and achievable goal in patients with 
both early disease and severe RA (66). 
The Early Rheumatoid Arthritis (ERA) trial which compared etanercept vs. MTX 
monotherapy in patients with early erosive RA found that although both drugs were 
associated with a reduction in disease activity and radiological joint damage, the ACR20 
response in the etanercept group was significantly higher than for MTX at 24 months (72% 
vs. 59%, respectively, p = 0.005) (74).      
In contrast, the Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes 
(TEMPO) study showed that the combination of etanercept and MTX was significantly better 
in reducing disease activity, improving functional disability and retarding radiographic 
progression compared with MTX or etanercept alone. Importantly 75% of patients achieved 
an ACR20 in the methotrexate only group compared to 85% of patients in the combination 
group who achieved ACR20 (p = 0.005). This finding reiterates the efficacy and use of MTX 
as first line therapy especially in a resource limited setting (75).  
In SA, the RA treatment guidelines for use of biological therapy recommend a six month trial 




biological agents can be initiated. This approach is based on the evidence that up to one third 
of all patients will achieve low disease activity on synthetic DMARD therapy alone, and the 
significant cost implications of biological agents in both the public and private health care 
sector (51). 
Surgical procedures for rheumatoid arthritis 
Surgical procedures play an important role in patients with long standing and advanced RA in 
improving pain and disability. The surgical options chosen depend on both the stage of 
disease and also the size and type of the joint involved. In general, total joint arthroplasty is 
preferred for large joints with severe disease, such as the knee, hip, shoulder or elbow (1). 
Total joint replacement (TJR) of the knee and hip accounts for a significant proportion of the 
cost of the disease (76). In a study by Wolfe and Zwillich (1998) it was estimated that 25% of 
all patients with RA between 1970 and through to the 1990 required TJR surgery (77). 
In SA, although surgical treatment is widely available, there are significant delays in joint 
replacements in the public health care sector due to resource constraints. Local studies have 
shown that delays in initiating medical treatment lead to a higher number of surgical 
interventions with up to 49.2% of RA patients requiring at least one surgical procedure. 
Significantly, of  these 15.6% had a replacement arthroplasty of one or more of the four 
major weight bearing joints (78). 
However, with the introduction of newer treatment options the need for joint surgery has 
decreased substantially in the developed world. The number of total hip and knee joint 
arthroplasties in patients’ with RA in Ireland decreased from 1995 to 2010, despite 
substantial increases in these procedures among the general population (79). Skytta et al, had 
similar findings in their study comparing trends in total knee replacements (TKR) in RA and 
osteoarthritis (OA), showing clearly reduced annual incidence of TKR in RA while steadily 
increasing incidence amongst OA patients. Both of these studies and several other reports 
suggest improving long term outcomes in RA (80, 81). 
Expert care 
The treatment of RA has been revolutionized in the last three decades and in association with 
improved drugs is the recognition that the involvement of a rheumatologist improves care and 




associated with better disease outcomes and decreased functional disability, compared with 
care rendered primarily by other clinicians. Further the importance of tight control, utilizing a 
treat-to-target strategy is best developed and maintained by an expert physician which 
ensures optimal patient outcomes (21, 51, 82). 
Unfortunately the number of rheumatologist in Africa is inadequate in comparison to the 
population. There are only 72 registered rheumatologists in SA for the 55 million population 
as of October 2016 (83) and there is no data on the distribution between public and private 
sector or the actual number of physicians in active practice. There are also no accurate 
published data on the number of rheumatologists in Africa. 
Long term outcomes in rheumatoid arthritis: functional and social outcomes 
Rheumatoid arthritis has a significant impact on health-related quality of life, and is 
associated with an increase in health care costs and mortality in affected patients compared 
with the general population. Due to severity of their disease and treatment delays a significant 
number of patients are unable to continue to work and become dependent on the state for 
their health care and social welfare support, resulting in an increase in the economic 
burden(29, 59, 84, 85). In contrast, early recognition and treatment of RA and maintenance of 
function will result in substantial reduction in the costs to society. 
Predictors for poor function include functional status at the onset of the disease, female 
gender, extent of inflammation, low levels of formal education and low socioeconomic status 
(86). 
Moreover apart from functional disability, RA has psychological effects including impact on 
overall quality of life and happiness levels. The psychological impact was clearly observed in 
patients living with RA in Soweto, “The experience of living with RA in a low resource 
context are similar to those in a mid and high resource contexts, but are exacerbated by 
poverty and lack of basic services. Pain and social exclusion are some of the key experiences 
of women with RA living in Soweto”(84). 
Mody et al. identified in a study in Kwa-Zulu Natal that pain, stiffness and financial problems 
were the main problems, emphasizing that clinical and laboratory markers do not describe the 
full impact of RA and its resultant joint inflammation and deformities (87). The evaluation of 




therefore incomplete and a focus on functional disability, psychological problems and 
associated handicaps with their repercussions is required (84). 
Prognosis 
Rheumatoid arthritis is a disease with a natural history of severe long term outcomes and is 
associated with a reduced life expectancy of a median of 10 years in men and 11 years in 
women (62, 85, 88). 
The overall mortality rate is two times greater than in the general population and the leading 
cause of death is ischemic heart disease. Patients at increased risk for death are those with 
extra-articular disease manifestations, low socioeconomic status, low education levels, 




Purpose of the study 
Contemporary epidemiological data on the prevalence and incidence of RA in SA is urgently 
required to improve recognition and care and inform policy making in RA (20). 
Importantly there is a need for tighter RA control in the SA public health care sector and 
Solomon et al, found that RA outcomes were poorer in the public health sector compared to 
the private health sector and better disease control is urgently required (61). 
The long term clinical, functional outcomes and mortality although well established in 
developed countries are also not well understood in the developing world and these 
parameters are important in informing future management guidelines. This study aims to 
examine disease activity and functional outcomes in patients with established RA for greater 
than ten years in an attempt to improve our understanding of the natural history and 
management of the disease in a SA in a multi-ethnic population. 
Specific Objectives 
 Describe the demographic profile of RA patients in a multi-ethnic public health care 
setting. 
 Describe the disease duration and document the proportion of sero-positive and sero-
negative RA patients. 
 To document the number of patients with active disease after a minimum of 10 years 
and to determine if standard care of practice are followed. 
 To describe disease activity in sero-positive and sero-negative patients with RA. 
 Describe the co-morbid disease profile and describe if standard of care received is in 
keeping with a tertiary institution. 







1. Kasper DL, Fauci AS, Hauser SL, et al. Immune mediated, Inflammatory and 
Rheumatologic Disorders. Harrisons Principles of Internal Medicine 19th edition ed: 
McGraw Hill; 2015. p. 2136-49. 
2. Grassi W, De Angelis R, Lamanna G, et al. The Clinical Features of Rheumatoid 
Arthritis. European Journal of Radiology. 1998; 27:S18-S24. 
3. Scott DL, Wolfe F, Huizinga TWJ, et al. Rheumatoid Arthritis. The Lancet. 2010; 
376: 1094-108. 
4. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. The New England 
Journal of Medicine 2011; 365:2205-19. 
5. Shmerling RH, Delbanco TL. The Rheumatoid Factor: An analysis of clinical utility. 
The American Journal of Medicine. 1991; 91(5):528-34. 
6. Farid SS, Gholamrezza A, Mirshafiey A. Anti-citruliinated protein antibodies and 
their clinical utility in rheumatoid arthritis. International Journal of Rheumatic Diseases. 
2013; 16:379-86. 
7. Taylor P, Gartemann J, Hsieh J, et al. A systematic review of serum biomarkers anti-
cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis. 
Autoimmune diseases. 2011. 
8. van der Helm-van Mil AHM, Verpoort KN, Breedveld FC, et al. Antibodies to 
citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis 
Research and Therapy. 2005; 7:949-58. 
9. Källberg H, Padyukov L, Plenge RM, et al the Epidemiological Investigation of 
Rheumatoid Arthritis (EIRA) study group. Gene-gene and gene-environment interactions 
involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. The 
American Journal of Human Genetics. 2007; 80:867-75. 
10. van Oosterhout M, Bajema I, Levarht EW, et al. Differences in synovial infiltrates 
between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic 
citrullinated peptide-negative rheumatoid arthritis. Arthritis and Rheumatology. 2008; 58:53-
60. 
11. Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association stydy mata-
analysis identifies seven new rheumatoid arthritis risk loci. Nature Genetics. 2010; 42:508-
14. 
12. Barton A, Worthington J. Genetic susceptibility to rheumatoid arthritis: an emerging 
picture. Arthritis Care and Research. 2009; 61:1441-6. 
13. Mody GM, Meyers OL. Rheumatoid arthritis in Blacks in South Africa. Annals of 
Rheumatic Disease. 1989: 69-72. 
14. Mody GM, Naidoo P. HLA association with rheumatoid arthritis in African Blacks. 
Journal of Rheumatology. 1989; 16:1326-8. 
15. Martell RW, Du Toit ED, Kalla AA, et al. Association of rheumatoid arthritis with 
HLA in three South African populations - Whites, Blacks and a population of mixed ancestry. 
South African Medical Journal. 1989; 76:189-90. 
16. Liao KP, Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid 
arthritis. Current Opinion in Rheumatology. 2009; 21:279-83. 
17. Hart JE, Laden F, Puett RC, et al. Exposure to Traffic Pollution and Increased Risk of 
Rheumatoid Arthritis. Environmental Health Perspectives. 2009; 17(7):1065-9. 
18. Chou CT, Pei L, Chang DM, et al. Prevalence of rheumatic diseases in Taiwan: a 





19. McGill PE, Oyoo GO. Rheumatoid arthritis in Sub-Saharan Africa. Annals of 
Rheumatic Disease. 1991; 50:965-6. 
20. Dowman B, Campbell R, Zgaga L, et al. Estimating the burden of rheumatoid arthritis 
in Africa: A systematic analysis. Journal of Global Health. 2012;2(2). 
21. Kalla AA, Tikly M. Rheumatoid arthritis in the developing world. Best Practice and 
Research Clinical Rheumatology. 2003; 17(5):863-75. 
22. Brighton SW, Meyers OL. The prevalence of rheumatoid arthritis in a rural African 
population. Journal of Rheumatology. 1988; 15:405-8. 
23. Beighton P, Solomon L, Valkenburg H. Rheumatoid arthritis in a rural South African 
negro population. Annals of Rheumatic Disease. 1975; 34:136-41. 
24. Solomon L, Robin G, Valkenburg HA. Rheumatoid arthritis in an urban South 
African Negro population. Annals of Rheumatic Disease. 1975(34). 
25. Mody GM. Rheumatoid Arthritis and Connective Tissue disorders: sub-Saharan 
Africa. Bailliere’s Clinical Rheumatology 1995; 9(1). 
26. Adebajo AO, Reid DM. The pattern of rheumatoid arthritis in West Africa and 
comparison with a cohort of British patients. Quarterly Journal of Medicine. 1991; 80:633-
40. 
27. Tikly M, Zannettou N, Hopley M. . A longitudinal study of rheumatoid arthritis in 
South Africans. GenMed Medscape. 2003; 5(1). 
28. Massardo L, Aguirre V, Garcia ME, et al. Clinical expression of rheumatoid arthritis 
in Chilean patients. Seminars in Arthritis and Rheumatism. 1995; 25(3):203-13. 
29. Mody GM, Cardiel M. Challenges in the management of rheumatoid arthritis in 
developing countries Best Practice and Research Clinical Rheumatology. 2008;22(4):621-41. 
30. Emery P. Treatment of rheumatoid arthritis. British Medical Journal. 2006; 332:152-
5. 
31. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of 
osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the 
Oslo Country Rheumatoid Arthritis Register. Arthritis and Rheumatism. 2000; 43:522-30. 
32. Van Staa TP, Geusens P, Bijlisma JWJ. Clinical assessment of the long term risk of 
fracture in patients with rheumatoid arthritis. Arthritis and Rheumatology. 2006; 
54(10):3104-12. 
33. Kalla AA, Bewerunge L, Langley A, et al. Trabecular bone density in premenopausal 
rheumatoid arthritis patients. South African Medical Journal. 2002; 92(1):62-8. 
34. Kalla AA, Meyers OL, Laubscher R. Prevalence of Metacarpal Osteopenia in Young 
Rheumatoid Arthritis Patients. Clinical Rheumatology. 1995; 14(6):617-25. 
35. Kalla AA, Meyers OL, van Wyk Kotze TJ, et al. Corticosteroid therapy and bone 
mass - comparison of systemic lupus erythematosus and rheumatoid arthritis. South African 
Medical Journal. 1995; 84(7):404-9. 
36. Emery P, Breedveld FC, Dougados M. Early referral recommendations for newly 
diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Annals of 
Rheumatic Disease. 2002; 61:290-7. 
37. Horton SC, Walsh C, Emery P. Established rheumatoid arthritis: Rationale for best 
practice - Physician's perspective of how to realize tight control in clinical practice. Best 
Practice and Research Clinical Rheumatology. 2011; 25:509-21. 
38. Hulsmans HMJ, Jacobs JWG, van der Heijde DMFM, et al The course of radiological 
damage during the first six years of rheumatoid arthritis. Arthritis and Rheumatology. 2000; 
43(9):1927-40. 
39. Tan YK, Conaghan PG. Imaging in rheumatoid arthritis. Best Practice and Research 




40. Tamai M, Kawakami A, Uetani M, et al. Early prediction of rheumatoid arthritis by 
serological variables and magnetic resonance imaging of the wrists and finger joints: results 
from prospective clinical examination. Annals of Rheumatic Disease. 2006; 65:134-5. 
41. Wolfe F. Comparitive usefulness of C-reactive protein and erythrocyte sedimentation 
rate in patients with rheumatoid arthritis. The Journal of Rheumatology. 1997; 24(8):1477-85. 
42. Davis MJ, Dawes PT, Fowler PD, et al. Comparison and evaluation of a disease 
activity index for use in patients with rheumatoid arthritis. Rheumatology (Oxford). 1990; 
29:111-5. 
43. Van der Heijde DMFM, Van Riel PLCM, Van Leeuwen MA, et al. Prognostic factors 
for radiographic damage and physical disability in early rheumatoid arthritis: A prospective 
follow-up study of 147 patients. Rheumatology (Oxford). 1992; 31(8):519. 
44. Yildirim K, Karatay S, Melikoglu MA, et al. Associations between acute phase 
reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. 
Annals of Clinical and Laboratory Science. 2004; 34(4):423-6. 
45. Kremers HM, Nicola PJ, Crawson CS, et al. Cardiovascular death in rheumatoid 
arthritis. Arthritis and Rheumatology. 2005; 52(3):722-32. 
46. Furst DE, Chang H, Greenberg JD, et al. Prevalence of low haemoglobin levels and 
association with other disease parameters in rheumatoid arthritis patients: evidence from the 
CORRONA registry. Clinical and Experimental Rheumatology. 2009; 27:560-6. 
47. Raj DS. Role of interleukin-6 in the anaemia of chronic disease. Seminars in Arthritis 
and Rheumatism. 2009; 42:545-9. 
48. Farr M, Scott DL, Constable TJ, et al Thrombocytosis of active rheumatoid disease. 
Annals of the Rheumatic diseases. 1983; 42(5):545-9. 
49. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid Arthritis Classification 
Criteria. Arthritis and Rheumatology. 2010; 62(9):2569-81. 
50. Smolen JS, Aletaha D. Assessment of Rheumatoid Arthritis Activity in Clinical Trials 
and Clinical Practice. UpToDate. [Internet]. 2016. 
51. Hodkinson B, Van Duuren E, Pettipher C, et al. South African recommendations for 
the management of rheumatoid arthritis. South African Medical Journal. 2013; 103(8):577-
85. 
52. Aletaha D, Smolen JS. The simplified disease activity index (SDAI) and the clinical 
disease activity index (CDAI) : A review of their usefulness and validity in rheumatoid 
arthritis. Clinical and Experimental Rheumatology. 2005; 23:100-8. 
53. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity 
measures: American College of Rheumatology recommendations for use in clinical practice. 
Arthritis Care and Research. 2012; 64(5):640-7. 
54. Liang MH, Jette A. Measuring functional ability in chronic arthritis Arthritis and 
Rheumatism. 1981; 24(1):80-6. 
55. Kalla AA, Smith PR, Brown GMM, et al. Responsiveness of Keitel functional index 
compared with laboratory measures of disease activity in rheumatoid arthritis. British Journal 
of Rheumatology. 1995; 34:141-9. 
56. Hochberg MC, Chang RW, Dwosh I, et al. The American College of Rheumatology 
1991 revised criteria for the classification of global functional status in rheumatoid arthritis. 
Arthritis and Rheumatology. 1992; 35:498-52. 
57. Steinbrocker O, Traeger C, Batterman RC, et al. Therapeutic criteria in Rheumatoid 
Arthritis JAMA. 1949;140(8):659-62. 
58. Mikuls TR. Comorbidity in Rheumatoid Arthritis. Best Practice and Research Clinical 
Rheumatology. 2003; 17(5):729-52. 
59. Michaud K, Wolfe F. Comorbidities in Rheumatoid Arthritis. Best Practice and 




60. Al-Bishri J, Attar SM, Bassuni N, et al. Comorbidity profile among patients with 
Rheumatoid Arthritis and the Impact on Prescriptions trend. Clinical Medical Insights 
Arthritis and Musculoskeletal Disorders. 2013;6. 
61. Solomon A, Christian BF, Dessein PH, et al. The need for tighter rheumatoid arthritis 
control in a South African public health care center. Seminars in Arthritis and Rheumatism. 
2005; 35(2). 
62. Minaur NJ, Jacoby R, Cosh JA, et al. Outcome after 40 years with Rheumatoid 
Arthritis: A Prospective Study of Function, Disease Activity and Mortality. The Journal of 
Rheumatology. 2004; 44(4). 
63. Kaplan MJ. Cardiovascular complications of Rheumatoid Arthritis – Assessment, 
prevention and Treatment. Rheumatic Diseases Clinics of North America. 2010;36:405-26. 
64. Dessein PH, Joffe BI, Veller MG, et al. Traditional and nontraditional cardiovascular 
risk factors are associated with atherosclerosis in rheumatoid arthritis. The Journal of 
Rheumatology. 2005; 32(3):435-42. 
65. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating Rheumatoid Arthritis to Target: 
Recommendations of an International Task Force. Annals of Rheumatic Disease. 2010; 
69(4):631-7. 
66. Breedveld FC, Kalden JR. Appropriate and Effective Management of Rheumatoid 
Arthritis. British Medical Journal. 2004:627-33. 
67. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined 
step down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early 
rheumatoid arthritis. The Lancet. 1997; 350:309-50. 
68. Mottonen T, Hannonen P, Leirisalo-Rapo M, et al. Comparison of combination 
therpay with single drug therapy in early rheumatoid arthritis: a randomised trial. The Lancet. 
1989; 353:1568-73. 
69. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with 
rheumatoid arthritis: a prospective study. The Lancet. 2002; 359:1173-7. 
70. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of 
traditional disease modifying antirheumatic drugs for rheumatoid arthritis: an observational 
study. Journal of Rheumatology. 2002; 29:1631-8. 
71. Hodkinson B, Musenge E, Ally M. Response to traditional disease-modifying anti-
rheumatic drugs in indigent South Africans with early rheumatoid arthritis Clinical 
Rheumatology. 2012; 31:613-9. 
72. Salliot C, Van der Heijde D. Long term safety of methotrexate monotherapy in 
patients with  rheumatoid arthritis: a systemic literature research. Annals of Rheumatic 
Disease. 2009; 68:1100-4. 
73. Wluka A, Buchbinder R, Mylvaganam A, et al. Long term methotrexate use in 
rheumatoid arthritis: 12 year followup of 460 patients treated in community practice. The 
Journal of Rheumatology. 2000; 27(8):1864-71. 
74. Bathon JM, Genovese MC. The Early Rheumatoid Arthritis Trial comparing the  
efficacy and safety of etanercept and methotrexate. Clinical and Experimental Rheumatology. 
2003; 21:195-7. 
75. Klareskog L, Van der Heijde D. Trial of Etanercept and Methotrexate with 
Radiographic Patient Outcomes. The Lancet. 2004; 363:675-81. 
76. Yelin E. Is early intervention worth it? Journal of Rheumatology. 2005;72:36-8. 
77. Wolfe F, Zwillich SH. The long term outcomes of rheumatoid arthritis: a 23 year 
prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients 
with rheumatoid arthritis. Arthritis and Rheumatism. 1998; 41:1072-82. 
78. Mody GM, Meyers OL, Reinach SG, et al. Surgical requirements in rheumatoid 




79. Harty L, O'Toole G, FitzGerald O, et al. Profound reduction in hospital admissions 
and musculoskeletal surgical procedures for rheumatoid arthritis with concurrent changes in 
clinical practice (1995-2010). Rheumatology (Oxford). 2015; 54(4):666-71. 
80. Sokka T. Is the long-term outcome of rheumatoid arthritis improving? Evidence from 
total joint replacement surgery. Future Rheumatology. 2007;2:237-9. 
81. Skytta E, Honakanen P, Eskelinen, et al. Fewer and older patients with rheumatoid 
arthritis need total knee replacement. Scandanavian Journal of Rheumatology. 2012; 
41(5):345-9. 
82. Rat AC, Henegaria V, Boissier MC. Do primary care physicians have a place in the 
management of rheumatoid arthritis. Joint Bone Spine 2004;71(190). 
83. Health Professionals Council of South Africa. http://www.hpcsa.co.za. 
84. Schneider M, Manabile E, Tikly M. Social Aspects of living with Rheumatoid 
Arthritis: a qualitative descriptive study in Soweto, South Africa – a low resource context. 
Biomed Central. 2008; 6(54). 
85. Pincus T. Long-term outcomes in rheumatoid arthritis. British Journal of 
Rheumatology. 1995; 34:59-73. 
86. Polina P, Ramiro S, Andras KP, et al. Lower education and living in countries with 
lower wealth are associated with higher disease activity in rheumatoid arthritis: results from 
the multinational COMORA study. Annals of Rheumatic Disease. 2016; 75:540-6. 
87. Naidoo P, Lindegger G, Mody GM. Socio-demographic and psychological predictors 
of rheumatoid arthritis health outcome. South African Journal of Psychiatry. 2004;10(4). 
88. Sokka T. Long-term outcomes of rheumatoid arthritis. Current Opinion in 
Rheumatology. 2009;21:284-90 
89. Wolfe F, Michell D, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis 




















Chapter 2: Manuscript 
 
A retrospective review of the demographic profile, disease activity, co-existent co-




Rheumatoid arthritis (RA) is a chronic inflammatory disease resulting in progressive joint 
damage and physical disability. Although thought to be rare in Africans, recent studies show 
an increasing incidence of RA in developing countries. Despite this, there is little attention 
focused on rheumatic diseases in Africa and there is a paucity of local research.  
Aim  
To describe the demographic profile of RA patients at a public sector arthritis clinic and their 
clinical disease activity, functional outcomes, drug therapy and co-existent co-morbid 
disease. 
Methods  
A retrospective chart review was conducted of the files of all RA patients attending the 
arthritis clinic at King Edward VIII Hospital, for a period of at least ten years. All RA 
patients were included provided they were still attending the clinic. Patients with overlap 
syndromes and other arthritides were excluded. The demographic data, duration of 
symptoms, initial presentation, serological status, current disease activity, functional class, 
co-morbid diseases, laboratory results, radiological investigations and treatment were 
recorded on a structured data collection tool. Data was analyzed using Stata statistical 
software package. Ethics approval was obtained from the KwaZulu Natal University 
Bioethical Research Committee. 
Results  
 The majority of patients were Indians (n=81, 58.7%) followed by Blacks (n = 51, 36.9%). 
Indian patients (93.8%) were more likely to live in urban areas compared to Black patients 




diagnosis of RA, on the initial visit, with 73 (63.5%) having a positive rheumatoid factor 
(RF). There was a significant association between initial RF positivity and current RF 
positivity (p < 0.0001); indicating that serological status did not change with treatment. 
Further, a positive association was observed between RF positivity and anti-cyclic 
citrullinated peptide test (p = 0.0120). Synovitis was still observed in 35.5% of patients at 
their last visit and in these patients the C-reactive protein remained elevated at ≥ 16 mg/dL (p 
< 0.0001). Radiographs showed a significant deterioration in terms of erosions between the 
two time points (p < 0.021). The majority of patients were on methotrexate therapy (n = 90, 
65.7%) and 73 patients (53.3%) were on more than one disease modifying anti-rheumatic 
drugs. Hypertension was the most frequent co-morbid disease seen in 96 (69.6%) patients.   
Conclusion  
This study found that despite patients having established RA for greater than ten years, a third 
of patients still had active disease. This highlights the need for a well-defined rheumatology 






Rheumatoid arthritis (RA) was thought to be rare in Africa, however in keeping with the 
increase in non-communicable diseases (NCDs) seen in developing countries, the prevalence 
of RA is also increasing (1, 2) . Rheumatoid arthritis can result in significant deformities if 
untreated. Life expectancy is reduced and most patients will experience diminished quality of 
life (3-6). 
There is limited data on the long-term outcomes of RA, and most studies have only included 
a minority of all patients with RA, and further research in this area is required (3). 
In contrast, there have been significant advances in the understanding of the pathophysiology 
of RA and the advent of potent new biologic therapies which have resulted in a paradigm 
shift emphasizing the need for earlier recognition, treatment initiation and treat to target 
remission (7, 8). This strategy has resulted in improved patient outcomes in regard to disease 
activity and functional class (9-12). 
In developing countries, including South Africa (SA), early diagnosis and optimal treatment 
of RA remain a challenge as the focus of public health care remains on treating 
communicable diseases (13). This is despite the increasing evidence that the prevalence of 
RA is rising in sub-Saharan Africa, possibly related to urbanisation, with the lower socio-
economic groups bearing the brunt the disease (1, 14). 
There are limited epidemiological studies in RA from SA, and only one longitudinal 
retrospective study on RA, describing the functional outcomes and response to disease 
modifying anti-rheumatic drugs (DMARDs) (15). Therefore, there are significant gaps in the 
knowledge of the natural history and outcomes of RA in a local resource constrained setting. 
This is compounded by a shortage of rheumatologists and prohibitively high costs of newer 
DMARDs which pose a challenge to delivering rheumatic care (15-17). 
This study describes the local experience of treating established RA in a tertiary care centre 
with respect to long term outcomes, drug management and co-existent co-morbid disease. 
These findings may be used to review and modify public health care policies, to raise 
awareness and recognition that early aggressive treatment of RA may result in health care 






Ethical approval for the study was obtained from the Biomedical Research Ethics Committee 
of the University of KwaZulu Natal (KZN), management of King Edward VIII Hospital 
(KEH VIII) and the provincial department of Health KZN.  
This study was conducted in eThekwini, at KEH VIII hospital which is a tertiary hospital, 
first established in 1936 during the apartheid government and therefore historically served 
mainly the Black and Indian population. 
A rheumatology clinic was established in the 1980’s, and in 2003 when the rheumatology 
department moved to Inkosi Albert Luthuli Central hospital, this clinic continued to function 
but under the care of trained medical officers. In April 2015, the clinic once more became a 
specialist-based clinic.  
A retrospective chart review of all patients with a clinical diagnosis of RA was conducted in 
June 2016. Inclusion criteria for the study were a minimum of ten years disease duration, 
confirmed diagnosis of RA and current attendance at the clinic. Patients with concomitant 
connective tissue diseases, or other forms of arthritis were excluded.  
The demographic data including age, ethnicity defined according to file and gender were 
recorded. The date of first visit, duration of symptoms, initial presentation, period of follow up, 
serological status (rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody 
(ACPA), current disease activity, functional class (FC), co-morbid diseases, laboratory results 
(haemoglobin, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)), 
radiological investigations and treatment were recorded on a structured data collection tool 
(Appendix 4). 
A total of 152 files of patients with established RA were reviewed. Fourteen patients were 
excluded from the study either because of insufficient clinical data or because only one visit 
was recorded. 
Each file was assigned with a unique study number and the data was captured onto an Excel 







Data was analyzed using Stata version 14 (StataCorp. 2015). Means/medians and frequencies 
were used to describe the data. Differences in continuous variables between groups were 
analyzed using the Wilcoxon Mann-Whitney test. Associations between categorical variables 
were analyzed using the Pearson chi square test or, where expected cell counts were less than 
5, Fisher’s exact test was instead utilised. Results were considered statistically significant for 
p-values less than 0.05. 
Results 
Demographic profile: Ethnic, age and gender distribution 
The majority of patients were Indian (n = 81, 58.7%) followed by Blacks (n = 51, 37.0%), 
while Coloureds (n = 5, 3.6%) and Whites (n = 1, 0.7%) made up a minority. 
The mean age of the total group was 63.7 years ± 10.6 years, with a range of 41 to 92 years. 
There were 120 (87%) woman and only 18 men (13%), and the female to male ratio was 
6.6:1.The female to male ratio was higher in Black patients compared to Indians at a ratio of 
9.2:1 vs. 7.1:1 (Table 1).  
The majority of Indian and Black patients resided in an urban area 63.6%, with only 19.7% 
and 16.7% living in a peri-urban or rural area respectively. Indian patients were significantly 
more likely to reside in an urban area compared to Black patients (93.8% vs. 15.7%, p = 
0.000).  
Disease history 
The mean age of disease onset was 41.7 years ± 11.0 years, with a similar mean age of onset 
in both the Indian and Black population group at 41.3 years ± 9.7 years vs. 42.7years  ± 12.6 
years respectively (p = 0.486) (Table 1). 
The median duration between symptom onset and first presentation to an arthritis clinic was 
2.0 years with an interquartile range (IQR) of 1 to 4 years. There was no significant difference 
in time to presentation between urban and rural dwellers (p = 0.934) or between Indian and 




The mean duration of established RA in patients was 21.8 years ± 7.0 years, with similar 
duration of disease in Indian and Black patients (21.1 years ± 6.6 years vs. 21.6 years ± 7.7 
years respectively). 
The mean follow-up time at the clinic was 17.4 years ± 6.1 years amongst all patients. 
Table 1. Demographic profile of Indian and Black patients and disease history 
 
Indians (n = 81) Blacks (n = 51) p-value 
Gender, n (%) 
   
Men 10 (12.3) 5 (9.8) 
 
Woman 71 (87.7) 46 (90.2) 
 
Gender ratio F:M 7.1:1 9.2:1 0.654 
Age (years) mean (±SD) 
   
Current 62.8 ± 10.2 64.2 ± 11.3 0.463 
Age at Onset1 41.3 ± 9.7 42.7 ± 12.6 0.486 
Residence, n (%) 
   
Urban 76 (94.0) 8 (15.7) 
 
Peri-urban 4 (5.0) 22 (43.1) 
 
Rural 1 (1.0) 21 (41.2) 0.001 
Disease duration1, mean (±SD) 21.1 ± 6.6 21.6 ± 7.7 0.677 
Time (years) delay before 
presentation1, median (IQR) 
2 (1-4) 2 (1-5) 0.420 
Follow up (years) at arthritis clinic2, 
mean (±SD) 
17.1 ± 6.6 18.0 ±5.5 0.446 
1Based on n = 75 Indians, n = 49 Blacks 







Pattern of disease distribution, deformities and extra-articular manifestation 
The majority of patients (83.7%) had a symmetrical poly-articular pattern of disease with 
small joint involvement in a rheumatoid distribution at their initial presentation and only 
16.4% of patients had evidence of established hand deformities. In contrast, 78 patients 
(67.2%) had hand deformities at their last visit (p = 0.006). 
Extra-articular features documented at initial visit were specifically rheumatoid nodules and 
sicca symptoms (n = 17 and n = 22 respectively). The most common manifestation was sicca 
symptoms (19.5%), which remained significantly positive at the last visit (p=0.000). 
Subcutaneous nodules were found only in 17 patients on the initial visit and only four 
patients had rheumatoid nodules at last visit. 
Serological status 
An initial RF serology was only available in 115 patients files, and the majority were positive 
for RF (n = 73, 63.5%). There was no significant difference in the serological status between 
Indians and Blacks (62.7% vs.65.1%; p = 0.841) at the initial visit.  
The RF and ACPA tests were repeated during the last year in 77 and 65 patients respectively. 
There was a significant positive association between the presence of the two serological tests 
(74% RF vs. 76.9% CCP; p = 0.012). Further a positive ACPA test correlated significantly to 
urban residence (p = 0.019) and was significantly more common in the Indian than in the 
African population group (57.4% vs. 42.6%; p = 0.041). 
Only nine patients that were RF negative at the initial visit, tested RF positive at the last visit, 
indicating a significant association between initial RF and current RF (p < 0.0001). 
Disease activity 
Disease activity was measured using early morning stiffness (EMS), active synovitis as 
documented in clinical notes and acute phase reactants (APR). 
The mean duration of EMS decreased significantly from 120.4 minutes ± 89 minutes at the 




The number of patients with active synovitis had also decreased significantly on reassessment 
(81% vs. 35.5%; p < 0.001) and no significant difference was noted between RF or ACPA 
serological status of patients and disease activity (p = 0.113 and p = 0.513 respectively). 
Although a significant decrease in synovitis was observed clinically, the mean ESR was not 
significantly different between the two time points (54.3 mm/hr. ± 28.4 mm/hr. vs.51.8 
mm/hr.± 35.7 mm/hr.; p = 0.478) (Table 2). 
C-reactive protein measurements were not routinely performed in the arthritis clinic initially 
and therefore have only been documented in the last two years. The median CRP, measured 
at the last clinic visit was 9 mg/dL (IQR 5mg/dL - 24mg/dL) (Table 2). Further, unlike the 
ESR findings, a CRP ≥ 16 mg/dL was significantly more often observed in patients who had 
clinically active disease compared to patients in remission (n = 47 vs. n = 87; p < 0.0001). 
A significant increase in the mean haemoglobin (11.7 g/dL ±1.4 g/dL vs. 12.2 g/dL ± 1.5 
g/dL respectively; p = 0.003) (Table 2) and decrease in the mean platelet count (363.5 cells x 
109/L vs. 296 cells x 109/L; p < 0.0001) was observed between initial and latest 
haematological results which also was associated with a decrease in disease activity. 
Table 2. Laboratory investigations at initial and last visit 
 
Initial visit Last visit p-value 
Erythrocyte sedimentation rate 
(mm/hr.), mean (±SD) 
54.3 ± 28.4 51.8 ± 35.7 0.478 
C-reactive protein (mg/dL), median 
(IQR) 
 
9 (5 - 24) - 
Haemoglobin (g/dL), mean (±SD) 11.7 ± 1.4 12.2 ± 1.5 0.003 
Platelets (x 109/L), mean (±SD) 363.5 ± 106.8 296.0 ± 83.8 < 0.0001 
 
Functional class 





Patients who presented with FC I and FC II were more likely to remain in the same class or 
show a deterioration in their functional status. At the initial visit, 54 patients were in FC class 
1, while at the last visit only 30 were still in FC I and 18 patients had moved to FC II. Similarly 
of the 38 patients who were initially in FC II, 19 patients remained in FC II and 13 had 
deteriorated to a FC III at current visit. 
In contrast, patients who presented with a poorer FC, FC III and FC IV were more likely to 
improve from first visit and have a higher FC at the current visit. Of the 19 patients in FC III 
at first visit, 11 had improved to FC II and only 7 remained in FC III at current visit. All 3 of 
the patients who started in FC IV at first visit were now in FC III.  
Table 3. Functional class at the initial and last visit 
 Initial Visit  Last Visit  
Functional Class 
 
I II III IV 
I 54 30 18 6 0 
II 38 5 19 13 1 
III 19 1 11 7 0 
IV 3 0 0 3 0 
Total 114 36 48 29 1 
 
Radiographs 
Radiographs were available for comparison in only 42 patients between the two time points. 
Thirty five (83.3%) patients had RA changes at initial visit with 17 (40.5%) having erosions. 
A significant deterioration was observed on repeat radiographs and all radiographs now 
showed typical RA changes and erosions were present in 83.3% of radiographs (p = 0.021). 
Medical management 
The pattern and use of DMARDS (methotrexate (MTX), salazopyrine (SSZ), and chloroquine 
(CQ)) is described in 137 patients with only one patient excluded due to missing data. A 




one or two agents respectively and 11 patients (8%) were not on any DMARD therapy 
(Figure 1). 
 
Figure 1. Percentage of rheumatoid patients on disease modifying anti-rheumatic drugs 
The majority of patients 90 (65.7%) were on MTX therapy with only 18 patients (13.1%) having 
never been on MTX. The median dose of MTXwas17.5 mg (IQR 15 mg-20 mg) weekly and the mean 
number of years on MTX therapy was 12 years ± 4.2 years (Figure 2).  
There were 74 patients (54%) on SSZ and 55 patients (40.2%) on CQ either alone or in 
combination with MTX. Side effects were seen most commonly with SSZ and SSZ was 
discontinued in 33 (24.1%) patients, this was followed by CQ discontinuation in 27 (19.7%) 












































Figure 2. Current drug use and adverse effects resulting in cessation of drug therapy 
(%) 
Non-steroidal anti-inflammatory drugs and corticosteroids were the most frequently 
prescribed adjunctive therapy in 109 (79.6%) and 98 (71.5%) patients respectively. 
Paracetamol was prescribed in 71.7% and tramadol in 37% of patients (Figure 3). 
Bone protective drugs, calcium and vitamin D were prescribed in the majority with 100% and 
91.3% of patients on these drugs respectively. Other frequently prescribed drugs included 





















































Figure 3. Co-prescribed drugs in rheumatoid arthritis patients (%)  
Coexistent co-morbid disease 
The most frequent co-morbid condition was systemic hypertension (n= 96, 69.57%) and only 
29 (21%) patients had diabetes mellitus. Although 32.6% of patients were receiving statin 
therapy only 114 patients had confirmed fasting lipogram results with 27 (23.7%) patients 
meeting the diagnosis of dyslipidemia.  
A minority of patients 7 (5.2 %) had a diagnosis of human immunodeficiency virus (HIV) 
infection, subsequent to the initial visit. Bone mineral densitometry (BMD) test results were 
only available in 38 patients as the hospital DXA machine has not been functional for greater 
than two years. The majority of RA patients tested (79%) patients had osteoporosis as defined 
by a World Health Organization osteoporosis classification.  
Osteoarthritis (OA) either primary or secondary was noted to be present if documented on 
clinical examination and / or if reported on radiographic features. Osteoarthritis findings were 





































There were no significant differences in hypertension, diabetes mellitus, HIV, osteoporosis or 
OA between Indian and Black patients but dyslipidemia was significantly more common in 
Indian patients (Table 4).  








Systemic Hypertension 56 (69.1) 36 (70.6) 0.860 
Diabetes Mellitus  22 (27.2) 7 (13.7) 0.069 
Dyslipidemia1 22 (32.8) 5 (11.6) 0.012 
HIV 3 (3.8) 4 (7.8) 0.318 
Osteoporosis2 23 (82.1) 6 (75.0) 0.653 
Osteoarthritis3 50 (98.0) 36 (97.3) 0.818 
1Based on n = 67 Indians, n = 43 Blacks 
2Based on n = 28 Indians, n = 8 Blacks 
3Based on n = 51 Indians, n = 37 Blacks 
 
Surgery 
A total of 41 (29.7%) patients had an orthopedic procedure or arthroplasty. The mean number 
of procedures was 1 ± 0.63, and knee replacement surgery was the most frequently performed 
procedure with 63.4% of patients having at least one total knee replacement. 
A further 14.6% of patients had hip replacement surgery and 12.2% had arthroscopy 
performed. Only one patient each had any of the following procedures; ulnar styloid excision, 






The epidemiology and natural history of RA is well established in developed countries, but 
there are few studies from Africa. This is one the first studies to report RA outcomes in the 
Indian and Black population in SA, albeit limited to those attending the public sector for care. 
In this study the mean age of disease onset was 41.7 ± 11.0 years which is consistent with 
studies from Africa, Asia and Latin America which show a younger mean age at disease 
onset of ≤ 40 years (14, 18, 19) almost 10 years younger than Caucasians. 
Similarly the gender ratio of female to male at 6.6:1 is much higher than 2-3:1 reported from 
the USA and Europe (20) and is consistent with earlier SA studies by Mody et al, who found 
a ratio of 3.7:1 (18) and more recently Tikly et al who reported a female to male ratio of 6.9:1 
in Blacks (15). This higher female to male ratio is also seen in Latin American where women 
are far more frequently affected with a ratio of 7 - 8:1 (19). 
Although RA is more commonly seen in urban population, the high percentage of Black 
patients from a rural area is most likely explained on the basis of the apartheid racial 
segregation laws that existed in SA pre-1994. These laws affected Indians to a lesser degree 
(21). Additionally, there are several studies from SA that support a rural-urban gradient in 
RA distribution (22-24). The influence of urbanization has also been observed in Taiwan 
(25). The reason for an increased risk in urban areas is poorly understood but exposure to 
traffic pollution has been postulated to increase the likelihood of RA in industrialized regions 
(26). 
In the last decade, studies have clearly shown that established RA is more difficult to treat 
and one is unlikely to attain the same outcomes as with early treatment (27-29). In this study, 
duration of disease before referral was 3.9 years, which is about one year longer than that 
reported by Tikly et al (15), in a Soweto population . Further the investigators showed that a 
delay of greater than two years in referral for specialist care contributed to a poorer functional 
outcome even after three years of treatment. The reasons for late presentation may include 
lack of recognition of RA by primary care physicians and inadequate access to health care 
(15, 30-32). 
The diagnosis of RA in this study was based on the American College of Rheumatology 1987 




patients, depending on severity of disease and the isotype measured (34). Consistent with this 
63.5% of patients in this study had a positive test for RF. 
Additionally there was a significant association between the initial RF and the last RF test 
result suggesting that the RF status in our cohort did not change with therapy. Further, the 
failure to observe any significant association between  RF and the ACPA tests positivity with 
clinical disease activity, is in keeping with current recommendations that repeated testing of 
these serum autoantibodies adds no additional value to ongoing patient management (35). 
Although ACPA which is more specific than RF, was not available two decades ago, studies 
show a close correlation in the sensitivity of RF and more recent second generation ACPA 
tests (34, 36, 37). This study showed a significant correlation between the sensitivity of the 
two tests suggesting that RF could be still used as a screening test in resource limited settings.  
Additionally although ACPA was significantly more common in Indians, the frequency was 
not higher than the general population or even from studies from India (38). In contrast the 
higher incidence of ACPA in urban areas is in keeping with studies that suggest RA 
prevalence is common in urban areas (24, 25). 
In contrast to the study in Black South Africans by Mody et al, subcutaneous nodules were 
found in a low percentage in this study while sicca symptoms tended to be commoner, 
possibly as this was mixed a racial group (18). 
Further in this study, despite patient being on treatment for almost two decades, one third of 
patients still had active synovitis at last visit which is not congruent with current treatment 
aims in RA (39, 40). Possible reasons for continued disease activity include that disease 
scores such as the Clinical Disease Activity Index (CDAI) and Simplified Disease Activity 
Index (SDAI) were not used, and follow up annual radiography, and regular laboratory 
monitoring of disease activity were not routinely performed (anecdotal evidence from 
experience in clinic) which assist in treating to target and optimizing drug therapy (40). 
A study from the Gauteng Region Early Arthritis registry showed that inadequate drug 
therapy is a possibly an important determinant of ongoing disease activity. Hodkinson et al, 
found that less than one third of indigent patients with early RA (<2 years duration) achieved 
low disease activity at one year on traditional agents. Interestingly it was observed that failure 




show an adequate response to DMARDS at six months were unlikely to show further 
improvement at 12 months (17). 
Further the importance of tight control, utilizing a treat-to-target strategy, with a goal of 
remission or low disease activity is challenging in state clinics where the number of patients 
seen are usually large and where patients are generally assessed at three monthly or longer 
intervals (16). 
In addition to clinical assessment, CRP and ESR are used in composite disease scores. 
Although the ESR showed no significant decrease over time, CRP correlated well with the 
clinical assessment confirming its usefulness in assessing RA as it is not influenced by age, 
sex, biochemical variations of red blood cells and immunoglobulins (40-42). 
Anemia and thrombocytosis, have been consistently reported in the literature and are 
associated with disease activity (43, 44). In keeping with this there was a significant increase 
in the mean haemoglobin and decrease in the mean platelet count over the two time points 
which correlated significantly with the decrease in disease activity. Additionally Hodkinson 
et al, in a South African study among indigent patients showed that a lower haemoglobin 
level and increased platelet count were poor prognostic factors (17).  
The aim of early RA treatment is to prevent joint deformity and radiographic progression 
which adversely affects long-term outcome (3-5, 40). Although a significant decrease in EMS 
was observed in the study following commencement of treatment, to the contrary, established 
hand deformities were observed in a significantly greater number of patients at the last visit, 
once more underpinning inadequate disease control. Further, significant changes were 
observed on the limited radiographs performed supporting findings that radiographic 
progression occurs early, is progressive, correlates well with cumulative disease activity and 
may even occur in patients in clinical remission (4, 45). It is now understood that 
radiographic monitoring is critical in disease monitoring, observing the progression of 
previously existing joint damage and assessing new joint abnormalities to ensure delivery of 
optimal care (46).  
Additionally the aim of treatment is to restore functional activity and it is established that 
untreated RA leads to a decline in functional status (3). Paradoxically in this study, patients 
with better FC were more likely to deteriorate, while those with poorer functioning improved. 




aggressively and DMARDs were withheld in mild-moderate disease until there was clear 
evidence of joint damage or bone erosions (27).  
Despite patients initially not being aggressively treated, over time except for a small 
minority, DMARDs were prescribed in all patients and most patients were on combination 
DMARD therapy with MTX by their last visit. This study, similar to other studies confirmed 
the clinical efficacy and tolerability of MTX in RA even at relatively high doses (47-50). 
In contrast the ongoing use of prednisone amongst 71.5% of patients is concerning as long 
term observational studies have associated worsening functional outcome and mortality rates 
with prednisone therapy (51). 
The use of prolonged corticosteroids also add to underlying risk of osteoporosis seen in RA. 
The prevalence of osteoporosis, despite only a small percentage of patients having a DXA 
scan in this study, is  consistent with other studies in that  >75% of patients tested  had 
osteoporosis (52, 53).   
Apart from osteoporosis, several other NCDs are associated with RA, and this study 
confirmed hypertension as one of the most common co-morbidities observed (16, 54). 
Rheumatoid arthritis is an independent risk factor for atherosclerotic disease and together 
with traditional risk factors, patients with established RA have an increased cardiovascular 
(CVS) mortality rate. It is therefore ideal that holistic management should be offered at a 
single treatment point (54-56). 
Surgery in our study was lower compared to the developed world, possibly due to limited 
access to surgical procedures and lack of resources (14, 15). In contrast developed countries 
are showing declining rates of surgery due to improved treatment options (57, 58). 
Study limitations 
This was a retrospective study and therefore there were a number of files that had incomplete 
or missing data. Also due to the long time period under review there are inconsistencies in 
data that relate to the use of laboratory tests and details on combination DMARD therapy and 
lack of access to newer therapies. Further the clinical assessment of disease was performed 
by several clinicians and inter-observer variability is a shortcoming, and a composite disease 
activity score such as the CDAI or SDAI was not used to measure disease activity. The study 




therefore may also not be an accurate reflection of natural history of RA in SA. Additionally 
this was a relatively small sample size and long term outcome of mortality was not assessed.  
Conclusion 
There are well described differences in RA epidemiology in terms of age, gender and 
urbanization in developing countries. This study similarly found that woman are significantly 
more likely to have RA, patients present at a younger age and urbanization is significantly 
associated with positive ACPA status. Despite a significant decrease in synovitis after 
DMARDS were commenced, at least one third of all patients still had active disease and 
radiographs showed significant progression highlighting the need for better and tighter RA 
control in the South African public sector. 
Prospective studies with adequate representation of all ethnic groups are required to evaluate 
the challenges faced in delivering an effective rheumatology service and to look at the role of 
newer biologic therapies. Additionally long term studies that evaluate measures of damage 
with regard to disability are needed. This information will assist in planning local policies in 
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Title of Study 
A retrospective review of the demographic profile, disease activity, co-existent co-morbid 
disease and treatment in established rheumatoid arthritis patients in a tertiary/regional 
hospital.  
Purpose of Study  
Rheumatoid arthritis (RA) is a chronic inflammatory multi-systemic disease targeting the 
synovium, that untreated can result in significant deformities, leading to impaired functional 
outcome and major disability (1). Without treatment, life expectancy is reduced. This places a 
great burden on healthcare systems due to the increased morbidity and mortality associated 
with the disease. Further, the economic impact of treating RA is significant, and health care 
costs limit the appropriate medical care of many patients in developing countries (2).  
In Africa and South Africa (SA), similar to the rest of the developing world, the burden of 
communicable disease has overshadowed the focus on non-communicable diseases (NCD) 
including RA. This is despite mounting evidence that the prevalence of NCD is rising in sub-
Saharan Africa, with the lower socioeconomic groups bearing the brunt of increasing NCD 
(3). 
Both cross sectional and retrospective studies from Africa in recent years show RA is often 
severe and requires special attention (4-6). Despite this, little attention is given to rheumatic 
disease in Africa, with only a single rheumatologist providing care for the 16 million strong 
population of Kenya and thirty for the 40 million of South Africa as recently as 2003 (2). 
There are limited studies from Africa and SA on the burden of NCD especially RA with only 
a single study from SA on the long term experience of RA. Tikly et al. showed that patients 
treated in a dedicated rheumatic unit had significant improvement in disease activity scores 
(5). In Tikly et al. study disease activity declined significantly from the first to the last visit 
and methotrexate was associated with improved survival time compared to other disease 
modifying anti-rheumatic drugs (DMARDs). 
Similarly, our unit has been treating patients with rheumatoid arthritis for greater than 30 
years however there is minimal data on the long term outcomes and management of these 
patients.  There is a clear association with co-morbidities in RA and increased disease activity 
and joint damage. This study therefore seeks to understand the natural history of patients with 
rheumatoid arthritis treated in a tertiary/regional hospital. 
The findings of this descriptive study will be relevant to clinicians working under similar 
circumstances in South Africa and other developing countries.  They can potentially assist 
with policy implementation in the treatment of RA patients and will probably highlight 







To describe the demographic profile of patients with long standing established rheumatoid 
arthritis (greater than 10 years), attending a public sector arthritis clinic and their disease 
status and management. 
Specific Objectives 
1. Describe the demographic profile of RA patients in a multi-ethnic public health 
care setting. 
2. Describe the disease duration and document the proportion of sero-positive and 
sero-negative RA patients. 
3. To document the number of patients with active disease after a minimum of 10 
years and to determine if standard care of practice are followed 
4. To describe disease activity in sero-positive and sero-negative RA patients. 
5. Describe the co-morbid disease profile and describe if standard of care received is 
in keeping with a tertiary institution. 
6. To document the use of disease modifying anti-rheumatic drugs in this cohort. 
Keywords 
Rheumatoid arthritis, positive rheumatoid factor, comorbid disease, disease activity, disease 
modifying anti-rheumatic drugs, South Africa 
Background and Literature 
Introduction 
Rheumatoid arthritis is a chronic inflammatory disease of unknown aetiology characterized 
by a symmetric, peripheral polyarthritis. It is the most common form of chronic inflammatory 
arthritis and often results in joint damage, physical disability and premature mortality (1). 
In addition, RA is associated with extra-articular manifestations including, but not limited to, 
subcutaneous nodules, lung involvement, pericarditis, peripheral neuropathy, vasculitis and 
haematological abnormalities (1). 
Pathogenesis of rheumatoid arthritis 
The pathogenic mechanisms of synovial inflammation in RA are driven by immune 
dysregulation, inflammation and a breakdown in self-tolerance. Multiple pathogenic 
mechanisms have been proposed, and a key pathway is the overproduction and over-
expression of tumour necrosis factor (TNF), which results in both synovial inflammation and 
joint destruction (8, 9) 
The causes of TNF overproduction include interaction between T and B lymphocytes, 
synovial-like fibroblasts and macrophages, leading to overproduction of several cytokines 
including interleukin-6 (IL6) which further drives persistent inflammation and leads to the 




chondrocyte and osteoclast activation (the latter primarily via the receptor activator of nuclear 
factor Kappa β ligand (RANKL–RANK system)) [Figure1](8, 10). 
 
 
Figure 1. Pathogenesis of rheumatoid arthritis [10] 
Rheumatoid arthritis synovium contains a predominantly T lymphocyte infiltrate, composed 
mainly of CD4+ cells. The functional role of these T cells remains poorly understood and 
direct targeting of these T cells with cyclosporine or T cell depleting therapies showed 
limited or no efficacy. These finding suggests that specific T cell subsets may need to be 
targeted and attention has increasingly focused on the role of type 17 helper T cells (Th17) 
which induce macrophages to secrete proinflammatory cytokines and help B cells to produce 
(auto)antibodies that bind to target antigens forming immune complexes [Figure 1] (9, 10). 
Apart from the accumulation of T cells, the rheumatoid synovium is also characterized by the 
infiltration of a variable number of B cells and antibody producing plasma cells supporting 
the theory that humoral adaptive immunity is integral to RA. The pathogenic role of CD20+ 
B cells is confirmed by the efficacy of rituximab, a monoclonal antibody directed against 
CD20 in RA patients (10). 
Additionally several other mechanisms have been implicated including the  activation of the 
innate immune system, intracellular signalling pathways including the Janus kinase (JAK) 
pathways and mesencymal tissue response which all contribute to the complex interplay of 
inflammation in RA and continue to be investigated in search for newer more effective 





Autoantibodies in rheumatoid arthritis 
Rheumatoid factor autoantibodies are found in 75-80% of RA patients at some time during 
the course of the disease. Immunoglobulin M (IgM) and immunoglobulin A (IgA) 
rheumatoid factors are key pathogenic markers directed against the Fc fragment of 
immunoglobulin (IgG). High titre of IgM RF are relatively specific for the diagnosis of RA in 
the setting of a chronic inflammatory polyarthritis and were for decades the only serological 
criterion widely used in the diagnosis of RA (1).  
More recently identified and increasingly important antibodies, are those directed against 
citrullinated peptides. Anti-cyclic citrullinated peptide (CCP) antibodies are produced in the 
liver and are directed against deaminated peptides. These antibodies recognize citrulline- 
containing regions of several different matrix proteins including filaggrin, keratin, fibrinogen 
and vimentin and are found in higher concentrations in the joint fluid than in the serum (1, 
11).   
The majority of patients with anti-citrullinated protein antibody (ACPA) positive disease are 
also positive for RF, however anti-CCP antibodies have a higher specificity for RA. The 
sensitivity of ACPA assays for RA varies from about 50 to 75%, depending upon the assay 
and study population, while specificity of ACPA is relatively high, usually over 90%. 
Positive ACPA testing also appears to predict an increased risk for progressive joint damage 
and radiographic progression more effectively than RF (11-13) 
Genetic Factors  
A clear relationship exists between genetic factors and RA with at least a 50% risk of 
developing RA being attributable to genetic factors. There are more than 30 genetic regions 
associated with RA, the major identified areas are PTPN22 and human leucocyte antigen 
(HLA) genes (14, 15).  
Genetic studies of the HLA-DR alleles found that the DR4 allele was the most common 
association among South African patients. Mody et al. found that the frequency of DR4 was 
44% in Blacks of Zulu descent in Durban with RA compared to 10% in matched control 
subjects (16). Similarly studies from Cape Town in Whites, Blacks and patients of Mixed 
Ancestry also showed a consistent association of HLA – DR4 in all population groups with a 
relative risk of 3,2 in Whites, 3,9 in Blacks and 3,7 in patients of Mixed Ancestry with RA 
(17).        
The HLA alleles share a common motive, which is known as the shared epitope and recent 
genetic studies show differences in ACPA status of patients with RA, which relate to the 
number of specific HLA-DRB1 alleles (14, 15). 
Environmental Factors 
Several environmental risk factors are thought to increase the risk of RA and the best studied 
amongst them is smoking. Smoking doubles the risk of developing RA especially in ACPA-




Other potential environmental risk factors are alcohol, coffee, vitamin D status, oral 
contraceptive use and a low socioeconomic status (19). 
Epidemiology of rheumatoid arthritis 
There is a wide geographically and ethnic variation in the prevalence of RA within countries. 
The native American Pima Indians of North America have one of the highest prevalence rates 
(7%) while other population studies from Africa and Asia show lower prevalence rates in the 
range of 0.2-0.4% [Figure 2] (1). 
 
Figure 2. Prevalence rates of rheumatoid arthritis [7] 
 
Rheumatoid arthritis affects approximately 0.5-1% of adults in the developed world. The 
disease is three times more common in women than men with prevalence increasing with age 
in both sexes. The highest prevalence is seen in women aged 65 years and over, suggesting a 
possible role for hormonal factors (1). 
There are limited studies on RA from Africa and these have been concentrated in a few 
countries (SA, Nigeria and Uganda) with no reported data from the rest of Africa (4).  
Although traditionally RA was thought to be rare in Africa and with a milder disease course, 
compared to the developed world, recent studies suggest an increasing incidence of RA. The 
first systematic literature review of the burden of RA in Africa by Dowman et al. (2011), 
showed a prevalence of 0.36% in 1990 which translates to a burden of 2.3 million affected 
individuals in 1990. Projections for 2010 based on the same prevalence rates would suggest a 
crude prevalence of 0.42% and the burden increased to 4.3 million people in Africa. This 
figure is thought to be an underestimation of the true burden of RA as it has been noted that 
hospital based studies under-report the prevalence by about 6 times in comparison to 
population based studies (4). 
The exact incidence of RA in Africa presently remains uncertain but there is mounting 




East, Central and South Africa, although it remains rare in West Africans (20). The few 
studies from SA show higher disease activity and prevalence in mixed urban community in 
Soweto (0.9%), compared to rural areas where both disease activity and prevalence is lower 
(Tswana of West Transvaal (0.1%), the Xhosa of Transkei (0.68%) and the Sotho’s in 
Lesotho (0.3%) Venda (0%)) (21-23). The reasons for the lower rates of RA in rural African 
populations remains unclear but the distinct urban rural gradient strongly supports 
environmental factors as an important causative role in the pathogenesis of RA. 
 Although the mean age of onset of RA at 36.6 years in Blacks is significantly lower than the 
44.2 years in Caucasians (24) there is no gender difference and in both groups there is a 
greater female preponderance of RA, similar to international reports (1). Genetic studies of 
the HLA DR alleles show that DR4 is the most common association and has been noted in 
patients of Zulu, Xhosa and Sotho descent in multi-center studies (1, 16, 17).  
Clinical manifestations and systemic consequences of rheumatoid arthritis 
Rheumatoid arthritis causes inflammation of the joints, tendons and bursae and subjects 
present with pain, swelling and early morning joint stiffness usually lasting more than one 
hour duration. The earliest affected joints are typically the small joints of the hands and feet 
and the initial pattern of joint involvement may be mono-articular, oligoarticular or 
polyarticular and usually in a symmetric distribution (1). 
Extraarticular manifestations may develop during the clinical course of RA or even prior to 
the onset of arthritis. Predictors for extra-articular disease are smoking, sero-positive RF 
disease and early onset of severe physical disability (25). The most frequently observed 
extraarticular manifestations worldwide are subcutaneous nodule, secondary Sjogren’s 
syndrome, pulmonary nodules and anaemia (1). The only study from SA, on the extra-
articular RA manifestations in African patients found a similar frequency and spectrum to the 
published literature (24, 26). 
Diagnostic Imaging  
Untreated RA is an aggressive disease and leads to bone erosions in 80% of patients within 
one year of diagnosis (10). Juxta-articular erosions are usually irreversible and characterize 
uncontrolled inflammation and are used as a measure disease activity. They are identified 
readily on hands and feet plain radiography. Two typical erosions are sufficient to confirm a 
diagnosis. Extensive ongoing damage on radiographs suggests inadequately controlled RA 
(8).  
Radiographs serve as a useful baseline for evaluating disease activity during treatment and 
should be repeated every two years in patients with remission or with low disease activity. 
Therapy is considered insufficient if there is radiological evidence of disease progression 
(25). 
There is irrefutable evidence that DMARD’s when used early in the course of the disease, 




Although conventional radiography was the diagnostic modality in RA, recently there has 
been extensive interest in new imaging modalities, particularly ultrasound (US) and magnetic 
resonance imaging (MRI) which can assess both reversible and irreversible structural changes 
(8) 
The advantages of the newer imaging techniques are a greater sensitivity in detecting 
synovitis, joint space narrowing and erosions earlier than conventional radiographs and the 
ability to provide unique additional information on disease activity (27). 
Ultrasound Doppler has useful negative predictive value in patients with high pre-test 
probabilities of development of RA (8). On a therapeutic front, precise visualisation of 
anatomical structures with bedside ultrasound facilitates allows for accurate placement of 
intra-articular injections, however, these are not yet part of routine patient management (7). 
The inter-observer variability and poor acoustic window, such as mid-carpus has to some 
extent restricted the value of US in routine practice despite widespread use in academic and 
research fields (8, 27). 
In contrast, MRI allows a three-dimensional perspective and precise assessment of the bony 
and soft tissue structures within a targeted joint. The main ‘activity’ findings detected by 
MRI include synovitis, tenosynovitis and bone marrow oedema (BME) while the ‘damage’ 
findings include bone erosions and joint space narrowing. The major limitation is that MRI 
criteria for diagnosis of RA are not uniformly defined, and the scoring system requires further 
detail, perhaps best decided by well-designed studies in this area (27). 
Tamai et al. reported a scoring system using baseline ACPA and/or RF, MRI findings of 
symmetrical synovitis and MRI BME and/or bone erosion which could predict early RA with 
82.5% sensitivity and 84.8% specificity (28). 
.Diagnostic Criteria 
As the understanding of the pathogenic mechanisms of RA have improved, this has led to the 
availability of new therapeutic drugs that have enhanced the management of RA. Moreover, 
it has been recognized that early therapeutic intervention improves clinical outcomes and 
reduces the accrual of joint damage and disability (29). 
These developments resulted in the American College of Rheumatology (ACR) revising the 
diagnostic classification criteria with the goal of identifying patients who would benefit from 
early effective intervention (29). The previous ACR1987 criteria were limited in identifying 
individuals with very early RA.  
In 2010, the ACR and the European League Against Rheumatism (EULAR) developed new 
classification criteria for RA, with the objective of improving sensitivity in detecting early 
disease (29). 
The new classification system redefines the current paradigm of RA by focusing on early 




stage features of erosive joint damage and extra-articular disease changes that can now be 
prevented with newer agents (8). 
The criteria assess joint involvement, autoantibody presence, acute phase response levels and 
symptom duration (Table1)  
Table 1. ACR/EULAR 2010 Rheumatoid Arthritis Classification Criteria  [8] 
  
Serum autoantibodies such as RF and ACPA are used as biomarkers for both diagnostic and 
prognostic significance and can precede the clinical manifestation of RA by many years (1). 
A small proportion of patients eventually diagnosed with RA may be positive for RF, but not 
for ACPA in the early stages of their presentation; thus measurement of both RF and ACPA, 
rather than ACPA alone, improves the specificity and sensitivity of serological testing for 
establishing a diagnosis of RA (12).  
Importantly prognosis varies within sero-positive and sero-negative disease respectively. 
Clinical studies demonstrate that RF and ACPA positive disease are different from 
autoantibody negative disease. The synovium of patients with ACPA positive disease have 
more lymphocytes compared with ACPA negative who have more fibrosis and increased 
thickness of the synovial layer (30).  
Moreover, higher titres of RF are found to correlate with extra-articular manifestations such 
as interstitial lung disease and vasculitis compared to RF negative disease. Although RF titres 
may fall with effective treatment of RA in patients who are originally RF-positive, this is not 






Disease Activity Assessment 
The success of therapy for RA relies on the goals of treatment to be specified in advance and 
to fulfil the response criteria that categorize improvement into either good or moderate 
response. The EULAR response criteria are based on the Disease Activity Score 28 (DAS 28) 
and thus measuring disease activity is an integral part of the management of RA (31). 
Common indicators of disease activity in RA include: 
 Pain 
 Swollen and tender joint counts 
 Patient and evaluator global assessment of disease activity 
 Erythrocyte sedimentation rate (ESR) and C-Reactive protein (CRP) 
 Duration of morning stiffness 
 Fatigue 
 Functional activity scales 
There are several methods of scoring disease activity in RA, where the clinical examination 
of tender and swollen joints, global assessments and laboratory investigations are combined 
in a composite disease activity score. The 3 validated scores currently in use in SA are the 
DAS-28, the Simplified Disease Activity Index (SDAI), and the Clinical Disease Activity 
Index (CDAI) (7).  
These scores allow classification into a state of remission, low, moderate or high disease 
activity and provides a simple tool for assessing disease at each patient visit to guide 
therapeutic decisions (7). The SDAI and CDAI were validated in their original studies in 
addition to several cross sectional cohorts. The Pearson correlation analysis between DAS28, 
SDAI and CDAI showed an excellent correlation between these scores and patients’ disease 
activity (31, 32).  
As active RA causes a substantial effect on physical functioning, instruments designed to 
measure physical function are useful indicators of disease activity. The complete Health 
Assessment Questionnaire (HAQ) is a comprehensive tool designed to assess patient 
disability, discomfort, medication, side effects, cost and mortality. Of these components only 
the HAQ Disability Index (HAQ-DI) is used frequently in clinical trials and clinical practice. 
It evaluates patients’ ability to perform activities of daily living through their self-reported 
answers to 20 questions designed to assess upper or lower extremity use (31). 
Finally while there are limitations inherent in the use of global ordinal scales, the ACR 1991 
global functional status in RA is a useful and accepted score to describe the global functional 
consequences of RA especially with regard to work disability (33). 
Acute phase response in rheumatoid arthritis 
The main clinically useful biologic markers in patients with RA include acute phase reactants 
(APR), particularly the ESR and the CRP. The APR describes the local and systemic 




The ESR level tends to correlate with disease activity in RA as well as disease severity and 
may be useful for monitoring therapeutic response (34). The use of ESR is limited by the 
size, shape and number of red cells as well as other plasma constituents such as 
immunoglobulins. 
The CRP is a more objective measure of disease activity in RA, however elevations of both 
CRP and ESR are stronger indications of radiological progression than CRP alone (35). In a 
study of 147 patients by Heijde et al, absence of progression of radiographic joint damage 
after two years was correctly predicted in 83% of the patients using a combination of disease 
activity at presentation (assessed by ESR, CRP, or disease activity score) and DR4 and RF 
positivity (36). 
In contrast Yildirim et al., reported an association between APR and DAS28, and showed the 
CRP was the most useful biochemical marker for evaluating the disease activity of patients 
with RA (37).  
Interestingly, these markers of systemic inflammation also confer a statistically significant 
increased risk for cardiovascular death among patients with RA, even after controlling for 
additional cardiovascular risk factors and comorbidities (25). Further, observational studies 
show an increased risk of cardiovascular disease (CVD), which correlates with the activity 
and duration of the RA measured by these APR’s (38). 
Other markers used include a low serum haemoglobin and low serum albumin in association 
with increased disease activity (39). A recent finding suggests that RA patients with anaemia 
have more severe disease. Mody et al. (1989) reported anaemia as the most common extra-
articular manifestation of RA in Black South Africans (26). It is postulated that the anaemia 
is mediated by inflammatory cytokines, in particular interleukin (IL6) (39, 40). Similarly, a 
reactive thrombocytosis associated with active RA is most likely due to the pro-inflammatory 
effects of interleukin1β and interleukin 4 (41). 
Rheumatoid arthritis and associated co-morbid diseases 
Rheumatoid arthritis is associated with an increased prevalence of other NCD. On average, 
the established RA patient has two or more comorbid conditions and these play a pivotal role 
in RA management and outcomes. It has been shown that the higher the number of comorbid 
illnesses, the higher the medical costs, disability and the risk of mortality. This is emphasized 
by Michaud and Wolfe in their seminal report on comorbidities in rheumatoid arthritis “It 
should be the responsibility of the rheumatologist to take this and the risk of additional 
conditions into account when treating the patient” (42). 
The NCD associated with RA are cardiovascular disease (CVD), infections, 
lymphoproliferative malignancy, gastrointestinal disease and osteoporosis (43).  
A small study by Bishri et al, of 340 patients with RA found that the most common 
comorbidities were hypertension (35.9%), diabetes (30.9%) osteoporosis (25.8%) and 
dyslipidaemia (19.4%) (44). Not surprisingly, it is now well established that CVD is the 




Rheumatoid arthritis and cardiovascular disease 
Accumulating evidence suggests that atherosclerosis and CVD are truly inflammatory 
disorders sharing a common pathophysiology with the synovial inflammation and pannus 
formation that characterize RA. Indeed it has been suggested that atherosclerosis and CVD be 
considered “extra-articular manifestations” of RA. Overlapping pathogenic features of the 
two diseases include the predominant role of pro-inflammatory cytokines (e.g. TNF alpha and 
IL-6) elevated serum levels of APR (including CRP, fibrinogen and serum amyloid), 
abnormal endothelial function and neoangiogenesis. The unchecked cellular dysregulation is 
postulated to account for the increased prevalence and severity of coronary calcification in 
RA (43, 46) 
In many ways, CVD in RA shares similarities with CVD in diabetes mellitus (DM). 
Preclinical atherosclerosis and the risk of CVD appears to be of equal frequency and severity 
in RA and DM of similar duration (46) and RA is associated with increased rates of 
cardiovascular illness, including myocardial infarction, cerebrovascular events and cardiac 
failure.  
Further, the medications used to treat RA might have dual effects on risk for cardiovascular 
(CV) morbidity. This is exemplified by the use of corticosteroids which may decrease CV 
complications in RA by decreasing inflammation but also increase CVD by promoting pro-
atherosclerotic lipid profiles, hypertension and insulin resistance (46). 
Therefore, it is now widely accepted that atherosclerosis in RA is associated with both 
traditional CV risk factors such as age and hypertension, as well as non-traditional risk 
factors of ongoing inflammation as in RA (47).  
Infection in rheumatoid arthritis and treatment associated comorbidity 
The increased rate of infection in RA is well documented when compared with a healthy 
control population. The increased risk is seen for all types of infections and for infections 
requiring hospital admission (43, 48). 
The risk is increased in patients with higher disease activity scores, and multiple co-
morbidities (diabetes, alcoholism, chronic lung disease) and the use of corticosteroids (48). 
The use of immunosuppressive agents which may impair immune function further increase 
the risk of serious infections, however McLean-Tooke et al, in a systematic review of the 
literature, reported minimal if any, increased infection risk in patients on low dose 
methotrexate (MTX) (48). 
In contrast, a meta-analysis of the risk of serious infection in patients on biological treatment 
found that standard dose and high dose biological drugs (with or without traditional 
DMARD’s) but not low dose biological drugs, were  associated with an increased risk of 




This is of particular interest in SA, where the increased use of biological drugs especially 
TNF alpha inhibitors pose a serious risk for development of tuberculosis (TB) infection due 
to the high burden of the TB endemic in sub-Saharan Africa and the essential role TNF plays 
in the containment of mycobacterial infection. Several studies have confirmed the 
relationship between use of infliximab (TNF inhibitor) and TB infection and the guidelines 
recommend that physicians should screen patients for latent TB infection or active disease 
prior to starting any biological treatment (50).  
The current recommendation is that TNF inhibitors as well as other biological agents should 
not be used in RA patients with ongoing active infection and should be used with caution in 
those with high risk of infection (i.e. diabetes mellitus, splenectomised patients) (43). 
In the South African context the high incidence and prevalence of human immunodeficiency 
virus (HIV) infection poses several challenges to the treatment of RA patients and 
information on the safety of using immunosuppressive drugs in an HIV infected patient is 
limited. Methotrexate and biologic drugs place patients at risk of opportunistic infections and 
there is concern about the effects of immunosuppression in an HIV-infected patient not on 
anti-retroviral therapy. It is therefore recommended in patients not on anti-retroviral therapy 
or who are virologically supressed that hydroxychloroquine (HCQ) (which may have 
antiviral properties) or sulphasalazine (SSZ) may be more appropriate choices (7). 
Rheumatoid Arthritis Treatment 
The aim of treatment in RA is the minimisation of disease activity using a combination of 
DMARDs and biological agents, with or without glucocorticoids according to the disease 
activity status. Achieving and maintaining low disease activity using a single or combination 
DMARDs as quickly as possible improves long term outcomes and is cost-effective 
compared with older, more gradual approaches to initiating DMARD therapy (1, 8) 
Disease modifying anti-rheumatic drugs are named because of their ability to slow or prevent 
structural progression of RA and were introduced in the 1970’s and early 1980’s. The most 
commonly used DMARD’s in the past were gold, penicillamine and minocycline all of which 
produced a slow response with an associated high level of toxicity, resulting in low 
compliance rates and due to their varying degrees of success and inconsistent clinical efficacy  
are no longer used (1, 7, 25) 
Later, drugs included HCQ and SSZ, both used for early mild disease or as adjunctive 
treatment (1). Although hydroxychloroquine has not been shown to delay radiographic 
progression of RA and is thus not considered to be a true DMARD, in contrast SSZ has been 
shown in randomized controlled trials to reduce radiographic progression of the disease (1). 
The introduction of MTX and its widespread use in the late 1980’s dramatically changed the 
therapeutic landscape of RA. Methotrexate was approved for the treatment of RA in 1986 and 
remains the drug of choice and the benchmark for testing efficacy and safety of all new 




Methotrexate is administered as long term therapy, usually in a range between 7.5 to 25mg 
weekly. The maximum therapeutic doses of MTX used in rheumatology practice has 
increased in recent years (8). Several studies show long term compliance and remission on 
MTX (51, 52). Choi et al. showed a 60% overall reduction in mortality in subjects on MTX 
(53).  
A systematic literature review on the long term safety of MTX monotherapy in patients with 
RA demonstrated good tolerability of the drug and favourable long term safety (54, 55). Data 
on MTX use and compliance show that approximately 60% of patients receiving high dose 
MTX (12.5mg/week) are still using the drug after 6 years and in a separate twelve year 
follow-up of 460 patients treated with MTX, 53% of patients were continuing to take MTX at 
12 years (irrespective of any periods of temporary discontinuation) (54). 
Methotrexate does, however, have several adverse effects with varying severity. The risk of 
MTX side effects is influenced by the dose and treatment regimen. Adverse effects of MTX 
include those that are minor (e.g. nausea) and those that are serious (e.g., hepatotoxicity, 
blood dyscrasias and interstitial lung disease). Monitoring of adverse effects includes, pre-
treatment screening and subsequent safety recording of blood counts and liver function tests 
should continue throughout the course of therapy (1). 
When MTX is contraindicated, sulfasalazine or leflunomide are alternatives (1). Disease 
modifying anti-rheumatic drugs are sometimes combined and several combinations of 
DMARD’s have proven efficacy (51, 52). An example is methotrexate, sulfasalazine and 
hydroxychloroquine – termed triple therapy. A randomised trial comparing combination 
therapy with single drug therapy MTX in early RA demonstrated that combination therapy 
was better and not more hazardous than single treatment in induction of remission in early 
RA (51). 
Biological Agents 
With the improved understanding of the pathogenesis of RA, biological DMARDs that are 
intravenous protein therapeutics targeting cytokines and cell surface molecules have been 
developed. These may be classified into TNF inhibitors and non-anti-TNF agents and these 
include, but are not limited to, B cell targeted therapy against CD20 such as rituximab, T cell 
co-stimulation blockade with the fusion protein abatacept and interleukin-6 receptor 
inhibition with tocilizumab (1, 8). 
The use of biological agents together with MTX has made clinical remission and 
radiographic non-progression a realistic and achievable goal in patients with early and severe 
RA (56). Investigators in the Early Rheumatoid Arthritis (ERA) trial comparing etanercept to 
methotrexate monotherapy showed a better ACR20 response in the etanercept group than that 
for MTX at 24 months (72% vs 59%, respectively, p =0.005) (57). 
Further, the Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes 
(TEMPO) study showed that the combination of etanercept and MTX was significantly better 




progression compared with MTX or etanercept alone (56). This highlights the pivotal role of 
methotrexate plays in RA therapy.  
In SA, the guidelines for use of biological therapy recommend a six month trial of at least 
three synthetic DMARDs (including MTX, unless contraindicated) before commencing 
biological agents. This seems reasonable, given resource constraints, and given that up to one 
third of all patients will achieve low disease activity on synthetic DMARD therapy (58, 59). 
Additionally, due to significant cost implications biological agents are limited in both the 
South African public and private health sector (7).  
Surgical Treatment 
Surgery in RA is reserved for severely damaged joints and while total joint replacements or 
arthroplasties may be done on any joint, the most successful procedures are carried out on 
hips, knees and shoulders. The goals of such surgery are to reduce disability, pain relief and 
improve quality of life (1). 
Although surgical treatment is widely available, there are significant delays in the public 
health care sector in SA due to costs and resource constraints. A multi-ethnic single entry 
survey of 256 RA patients in a specialized rheumatology and orthopaedic hospital in 1988, in 
Cape Town found that 49.2% of patients had at least one surgical procedure and that 15.6% 
had a replacement arthroplasty of one or more of the four major weight bearing joints (60).  
Fortunately due to better drug treatment, the need for joint surgery has decreased and a study 
from Ireland, showed the total number of hip and knee joint arthroplasties in patients with RA 
decreased from 1995 to 2010, despite substantial increases in those procedures among the 
general population (61).  
Expert Care 
There is convincing evidence that an expert in the treatment of rheumatic diseases, such as a 
rheumatologist, should participate in the care of patients with inflammatory arthritis who are 
suspected of having RA and the ongoing care of patients diagnosed with this condition. The 
initial and continued care of patients with RA by a rheumatologist is associated with better 
disease outcomes compared with care rendered primarily by other clinicians (2, 7, 62). 
Long term rheumatoid arthritis – prognosis, functional and social outcomes 
Rheumatoid arthritis is recognized as a disease with a natural history of severe long term 
outcomes (63, 64) and is associated with reduced life expectancy of a median of 10 years in 
men and 11 years in women (45). Significant predictors of poor function include functional 
statues, female gender and disease activity state at disease onset (65). 
Rheumatoid arthritis has a significant impact on health-related quality of life, and is 
associated with increased mortality and health care costs when compared to the general 




for their health services and social welfare support, resulting in psychological problems and 
an increasing economic burden for the country.  
However, with early successful treatment the patients can return to the workforce decreasing 
the burden on the state, resulting in a substantial reduction in the costs to society (42).  
The social aspects of living in RA have been studied in Soweto, SA and the following 
observation was made “The experience of living with RA in a low resource context are 
similar to those in a mid and high resource contexts, but are exacerbated by poverty and lack 
of basic services. Pain and social exclusion are some of the key experiences of women with 
RA living in Soweto” (66). 
Importantly, low levels of formal education and poor socioeconomic status have been 
identified as risk factors for poorer outcome in RA (67). 
South African Perspective 
Contemporary epidemiological data on the prevalence and incidence of RA in South Africa 
are limited to only a few studies (4, 20).  
There is only one recent study on the long term outcomes by Solomon et al, in established 
RA, and the study found a need for tighter RA control in the South African public health care 
sector, where results of disease outcome measurements were poorer in public care patients 
than in private care patients. This highlights the need for better disease activity control of RA 




This is a retrospective, descriptive chart review of established RA patients attending a tertiary 
arthritis public health sector clinic for a period greater than 10 years. 
Study Population 
Kwazulu Natal (KZN) has a multi-ethnic population which is unique because of its large 
Indian population (originally from the Indian sub-continent). According to Census South 
Africa (2011), KZN has a population of 10.2 million people, about 85% of whom are Black 
Africans followed by 9.5% Indian (68).  
 King Edward VIII hospital was established in 1936 for a mainly Black South African 
population because of racial segregation under the previous apartheid government and 
therefore the population serviced a mainly indigent Black/ Indian group of South Africans. 
The arthritis clinic was established in the early 1970’s, as a specialist based clinic, affiliated 
to the Department of Internal Medicine, University of Natal. Initially managed by physicians 




In 2003, a central tertiary hospital was opened and the rheumatology department along with 
other sub-specialties relocated to the new centre. The arthritis clinic continued to function in 
King Edward hospital but under the primary care of medical officers with an interest in 
rheumatology. There was no continuation of specialist rheumatologist care or specialist 
physician service for the clinic during this time. Therefore the majority of patients with active 
disease were transferred in 2003 and those patients who remained at the clinic were those 
who were unwilling to transfer or who were deemed to have early mild disease or disease 
remission. 
In April 2015 the clinic became a specialist based clinic, run by a rheumatologist and 
physicians with an interest in rheumatology and all files have been subsequently re-revised 
and patient management reviewed. 
Sampling strategy 
A carbonated copy of all file are kept for every patient in the clinic and all RA patient files 
will be reviewed. All files with RA with >10 years from diagnosis, with patients in current 
attendance, will be reviewed for the study purpose. 
Sample size 
All files of patients attending the clinic for greater than 10 years will be reviewed. 
Inclusion criteria 
All patients with established rheumatoid arthritis as defined by the clinical notes and by that 
fulfilled the 1987 ACR criteria.     
Exclusion criteria 
Patients with RA for less than 10 years duration.  
Patients who are no longer in attendance at the clinic. 
Patients with a diagnosis of psoriatic arthritis and/or overlap syndromes or  
Patients diagnosed with autoimmune disease. 
 
Data collection methods and tools 
The clinic files for all patients who meet inclusion criteria will be assessed and data 
extrapolated using a standardized data collection tool sheet.  
• The following data will be collected: clinical notes, radiological reports and 
laboratory results. 
• All data will be directly entered onto the data collection sheet by the principal 
investigator. 
• The data will be checked to ensure reliability and validity and to minimize error. 
• Sample bias will be eliminated as all patient files that meet inclusion criteria will 
be documented.  





1. Age  
2. Gender 
3. Ethnicity – will be documented as Black/Indian/Mixed Ancestry/Caucasian 
4. Date of diagnosis – the earliest recorded date of RA diagnosis or symptom onset will 
be considered the incidence date of disease. 
Clinical 
1. Number of tender and swollen joints 
 The number of tender and swollen joints noted at the most recent visit will be 
scored according to the SDAI and captured. 
2. Duration of early morning stiffness, at most recent visit, will be recorded. 
3. Modified functional class 
 This will be defined by the ACR 1991 revised criteria for the classification of 
global functional status in RA. 
4. Document the co-existent comorbid disease/s and the duration – at enrolment and at 
>10 years 
 Diabetes mellitus was recorded as present if there was a clearly documented 
history of diabetes and/or current treatment with hypoglycaemic agents. 
 Hypertension was recorded as present if there was a physician’s diagnosis of 
hypertension in the medical records and/or were receiving antihypertensive 
agents. 
 HIV was recorded present if there was a positive test result in the patient file 
and/or the patient receiving highly active anti-retroviral therapy. 
 Dyslipidaemia was defined according to the cut off values as recommended by 
the South African dyslipidaemia guidelines and or statin therapy  
 Osteoporosis was defined according to bone mineral density results and or 
treatment with bisphosphonates  
 Other : any other disease will be specified and duration 
5. Document the treatment 
 Use of DMARD therapy will be documented 
o Drug name 
o Duration 
o Reason for discontinuation 
 For each individual drug, as recorded in clinical notes will be recorded 
Investigations 
The following results as per last visit will be recorded: 
1. Haemoglobin 
 Hb < 12g/dL in females and Hb <13g/dL in males 
2. CRP 





 Sustained elevation of the ESR was defined as >2 recorded ESR values of 
>60mm/hr. with a minimum interval of 30 days between two measurements. 
4. RF 
 Rheumatoid factor will be documented as positive as documented by clinical 
notes and/or laboratory reports in patient’s files. 
5. ACPA 
 Anti citrullinated protein antibody test will be recorded as either present or 
absent. 
Imaging 
Radiographs done at initial assessment and reported on by a radiologist will be recorded as 
either present or absent in the following fields: 
 Erosions 
 Joint space narrowing 
 Juxta-articular osteopenia 
Osteoporosis 
The World Health Organization (WHO) Classification of osteoporosis was used for patients 
who had bone mineral densitometry scans done (69).       
The WHO criteria for the diagnosis of osteoporosis is shown in Table 2. 
Table 2. WHO Classification of Osteoporosis (69) 
Normal bone T-score better than -1 
Osteopenia T-score between -1 and -2 
Osteoporosis T-score less than -2.5 
Established osteoporosis Presence of a non-traumatic fracture 
 
Data management 
• Each file will be assigned a unique study number. 
• Data will be de-identified and captured onto an Excel spread-sheet and will be 
password protected. 
• Only the investigators will have access to the master copies.  
nly de-identified data will be submitted for analysis. 
Statistical analysis 





• Descriptive statistics and frequency tables will be used to report the demographic 
characteristics (age, gender and ethnicity) of the study population. 
• Cross tabulations and student t-tests will be used to determine age, gender and 
ethnicity specific differences. 
• Chi square will be used for categorical variables. 
• The significance of the test will be set at p<0.005 
Study location 
King Edward VIII Hospital is located in Durban, KZN. It is the second largest hospital in the 
southern hemisphere providing regional and tertiary services to the whole of KZN and parts 
of the Eastern Cape. King Edward is a 922 bedded hospital with approximately 360 000 out –
patients (70). 
It is a teaching hospital for the University of KwaZulu Natal (UKZN), Nelson R Mandela 
School of Medicine and has a nursing college attached to it with a full range of medical and 
surgical specialties (70).  
Study period  
This is a retrospective chart review of 2016. The patient files reviewed will cover a period 
from 1990-2016. 
Limitations to the study 
There are several limitations to the present study, many relating to its retrospective nature.  
These include absent or missing data, absence of a comparator group and lack of standard use 
of composite disease activity scores and ACR response criteria, now widely used in clinical 
trials, to indicate disease activity and remission. 
Inter-observer variability, as evaluations of patients were made by several clinicians over 
time, may result in poorly representative data, as does the lack of validated tools for 
measurement of disease activity. 
It was also not possible to assess the impact of the disease on employment status since this 
was, in most cases, only recorded at presentation and not on an on-going basis. Functional 
outcome has been used as a surrogate. 
Analysis of mortality was not possible as such data would not have been captured in the 
clinic files and those files that are not available. Further adherence rates cannot be calculated 
as no registry exists. 
The patient population in our clinic is biased with regard to ethnicity and race due to the 
country’s apartheid legacy as discussed above and will be pertinent to Indian and African 
population only. Furthermore, due to the transfer of the department of rheumatology to a 
central hospital in 2003, a significant proportion of patients were moved, resulting in a 




Finally, the patient in this clinic may represent patients with less aggressive disease and fewer 
extra-articular manifestations and therefore outcomes and use of DMARDS may differ 
compared to patients with more aggressive disease. Despite this there is such a paucity of 
data from SA on RA and this audit may still provide extremely valuable information in our 
setting.   
Timeline 
Submission of protocol to postgraduate office and for ethics approval – March 2016 
Collection of data – July to August 2016 
Analysis of data – September 2016 
Write up of findings – October to November 2016 
Ethical considerations 
Scientific Validity 
No audit of this nature has been done in this clinic before. This study is valid as it will 
provide relevant knowledge on the patient population, management and care of patients 
attending the King Edward VIII arthritis clinic. 
Confidentiality 
This is a retrospective chart review study. There will be no patient contact. Patients will be 
captured on the data collection tool using only their initials and study identity number. 
Informed Consent 
Informed consent was not obtained for the study as it is a retrospective chart review. Ethical 
approval will be obtained from the Biomedical Research ethical committee of UKZN and 
gatekeeper permission to obtain records will be obtained from King Edward VIII hospital and 
Department of Health. 
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Appendix 4: Data Collection Tool 
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